canonical_smiles,cp_id,PRISM_auc,name,moa,target
CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1,0,-1.0,RS-0481,immunostimulant,
C/C=C1\C(OC2OC(CO)C(O)C(O)C2O)OC=C(C(=O)OC)C1CC(=O)OCCc1ccc(O)c(O)c1,1,-1.0,oleuropein,estrogen receptor agonist,GPER1
CCC(C)C(N)C(=O)O,2,-1.0,isoleucine,,"ACADSB, BCAT1, BCAT2, IARS, IARS2"
CC(N)Cc1cccc(O)c1,3,-1.0,gepefrine,adrenergic receptor agonist,
CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,4,-1.0,cloranolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3"
CC(C)(C)NCC(O)c1cc(Br)no1,5,-1.0,broxaterol,adrenergic receptor agonist,ADRB2
CC(C)=CCC/C(C)=C/CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2,6,-1.0,SQ-109,bacterial cell wall synthesis inhibitor,FDFT1
CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O,7,-1.0,prolylleucylglycinamide,melanocyte-stimulating hormone release inhibitor,
CCCCCCCCCCCC(=O)OCC(O)CO,8,-1.0,glycerol-monolaurate,beta lactamase inhibitor,
CC(C)(C)NCC(O)c1cc(Cl)c(N)c(C(F)(F)F)c1,9,-1.0,mabuterol,adrenergic receptor agonist,ADRB2
NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2,10,-1.0,peficitinib,JAK inhibitor,"JAK1, JAK2, JAK3"
CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl,11,-1.0,clofedanol,histamine receptor antagonist,HRH1
CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,12,-1.0,polythiazide,sodium/chloride cotransporter inhibitor,SLC12A3
COCC(O)Cn1ccnc1[N+](=O)[O-],13,-1.0,misonidazole,,
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)C(O)(Cn1cncn1)c1cc(F)ccc1F,14,-1.0,isavuconazole,cytochrome P450 inhibitor,CYP3A4
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,15,-1.0,lercanidipine,calcium channel blocker,"CACNA2D1, CACNG1"
CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1,16,-1.0,clorotepine,"dopamine receptor antagonist, adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6"
CC1(S(=O)(=O)O)CC(=O)c2ccccc2C1=O,17,-1.0,menadione-bisulfite,vitamin K,"GGCX, VKORC1, VKORC1L1"
CC(C)NCC(O)c1ccc([N+](=O)[O-])cc1,18,-1.0,nifenalol,adrenergic receptor antagonist,"ADRB1, ADRB2"
Cc1cccc(OCC(O)CNC(C)(C)C)c1C,19,-1.0,xibenolol,adrenergic receptor antagonist,
CNC(C)Cc1ccccc1OC,20,-1.0,methoxyphenamine,adrenergic receptor agonist,
CC(=O)OC1[C@@H](N2CC[N+](C)(C)CC2)C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@@H](N5CC[N+](C)(C)CC5)C[C@]4(C)[C@H]3CC[C@]12C,21,-1.0,pipecuronium,neuromuscular blocker,"CHRM2, CHRM3, CHRNA2"
CC1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,22,-1.0,PF-06463922,ALK tyrosine kinase receptor inhibitor,"ALK, FES, ROS1"
CC(=O)NC(Cc1ccc(O)cc1)C(=O)O,23,-1.0,N-acetyl-tyrosine,,
CN(C)[C@@H]1C(=O)C(C(N)=O)C(=O)[C@@]2(O)C(=O)C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12,24,-1.0,chlortetracycline,protein synthesis inhibitor,
CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C,25,-1.0,butofilolol,adrenergic receptor antagonist,
C=C1CCN([C@H](C)C(O)(Cn2cncn2)c2ccc(F)cc2F)CC1,26,-1.0,efinaconazole,lanosterol demethylase inhibitor,CYP51A1
N=C1NCCC(C2NC(=O)/C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC2=O)N1,27,-1.0,capreomycin,protein synthesis inhibitor,
CNC(CC(C)C)C(=O)NC1C(=O)NC(CC(N)=O)C(=O)NC2C(=O)NC3C(=O)NC(C(=O)NC(C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)C(OC3CC(C)(N)C(O)C(C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3OC2OC(CO)C(O)C(O)C2OC2CC(C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)C(O)C(C)O2)Oc2ccc(cc2Cl)C1O,28,-1.0,oritavancin,bacterial cell wall synthesis inhibitor,
CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,29,-1.0,terodiline,cholinergic receptor antagonist,
Oc1ccc(C(O)CNCCCCCCNCC(O)c2ccc(O)c(O)c2)cc1O,30,-1.0,hexoprenaline,adrenergic receptor agonist,ADRB2
COc1ccc2c(c1)c(CC(=O)OCC(C(=O)O)c1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,31,-1.0,tropesin,cyclooxygenase inhibitor,"PTGS1, PTGS2"
CNC(C)CC1CCCCC1,32,-1.0,propylhexedrine,adrenergic receptor agonist,"SLC18A2, TAAR1"
CC(=O)NC1N=C(c2ccccc2)c2ccccc2NC1=O,33,-1.0,A-33903,,
Cc1ncc([N+](=O)[O-])n1CC(O)CN1CCOCC1,34,-1.0,morinidazole,other antibiotic,CYP51A1
CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C,35,-1.0,bacampicillin,bacterial cell wall synthesis inhibitor,
CC(CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,36,-1.0,cyamemazine,serotonin receptor antagonist,"HTR1A, HTR2A, HTR2C, HTR7"
CCC(O)(c1ccccc1)c1cccc(C(F)(F)F)c1,37,-1.0,flumecinol,,
O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,38,-1.0,AZD1446,acetylcholine receptor agonist,"CHRNA4, CHRNB2"
CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@]12C,39,-1.0,ginsenoside-rg3,"angiogenesis inhibitor, apoptosis stimulant",KCNH2
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,40,-1.0,ODM-201,androgen receptor antagonist,AR
CCC(C/C=C/c1ccccc1)(c1ccccc1)N(C)CC1CC1,41,-1.0,igmesine,sigma receptor agonist,SIGMAR1
Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1,42,-1.0,bupranolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3"
CCCCCCCC(=O)OCC(O)CO,43,-1.0,monoctanoin,,
CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,44,-1.0,carazolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3"
COc1cc(CC2NCCc3cc(O)c(O)cc32)cc(OC)c1OC,45,-1.0,trimethoquinol,adrenergic receptor antagonist,"ADRB2, ADRB3"
CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,46,-1.0,valethamate,acetylcholine receptor antagonist,"CHRM1, CHRM4, CHRM5"
CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1,47,-1.0,AMG319,PI3K inhibitor,PIK3CD
CCCCC1OC(=O)c2ccccc21,48,-1.0,butylphthalide,potassium channel antagonist,KCNK2
CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O,49,-1.0,netilmicin,protein synthesis inhibitor,
CC(C)CC1NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC(=O)O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O,50,-1.0,BQ-123,endothelin receptor antagonist,EDNRA
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1,51,-1.0,tolamolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3"
CC1Sc2c(C(=O)O)c(=O)c3cc(F)c(N4CCNCC4)cc3n21,52,-1.0,ulifloxacin,,
COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1,53,-1.0,enciprazine,GABA receptor modulator,GABRA1
CC(C)(C)C(=O)OCOC(=O)C1N2C(=O)CC2S(=O)(=O)C1(C)C,54,-1.0,sulbactam-pivoxil,beta lactamase inhibitor,
CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,55,-1.0,octreotide,somatostatin receptor agonist,"SSTR1, SSTR2, SSTR3, SSTR5"
CC1CCC2(NC1)OC1CC3C4CC=C5CC(OC6OC(CO)C(OC7OC(C)C(O)C(O)C7O)C(O)C6OC6OC(C)C(O)C(O)C6O)CCC5(C)C4CCC3(C)C1C2C,56,-1.0,solamargine,apoptosis inhibitor,
NC(=O)CN1CC(c2ccccc2)CC1=O,57,-1.0,phenylpiracetam,noradrenaline uptake inhibitor,
CO[C@@H]1[C@@H](OC2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,58,-1.0,spiramycin,bacterial 50S ribosomal subunit inhibitor,
CNC(=S)C1(c2ccccn2)CCCS1,59,-1.0,picartamide,H+/K+-ATPase inhibitor,ATP4A
CN1C(=O)C(N2CCCCC2)S/C1=C\C(=O)O,60,-1.0,ozolinone,diuretic,
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,61,-1.0,misoprostol,prostanoid receptor agonist,"PTGER2, PTGER3, PTGER4, PTGIR"
CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,62,-1.0,gadoteridol,radiopaque medium,
CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO,63,-1.0,beclomethasone,glucocorticoid receptor agonist,"NR3C1, SERPINA6"
CSc1ccccc1OCC(O)CNC(C)C,64,-1.0,tiprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3"
CN(C)C(=O)CCSC(SCCC(=O)O)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,65,-1.0,MK-571,leukotriene receptor antagonist,"ABCC2, CYSLTR1"
Cc1ccc(NC(=O)c2ccc(CN3CCC(N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1ncc(-c2cncnc2)cn1,66,0.936608143,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN"
Nc1ccc(C(=O)OCC(O)CO)cc1,67,-1.0,lisadimate,topical sunscreen agent,
COc1cc2nc(N3CCN(C(=O)C(C)OC)CC3)nc(N)c2cc1OC,68,-1.0,metazosin,adrenergic receptor antagonist,ADRA1A
COc1cc(C)c2c(Oc3cccc(C(F)(F)F)c3)c(OC)cc(NC(C)CCCN)c2n1,69,-1.0,tafenoquine,antimalarial agent,
CC(S)C(=O)NCC(=O)O,70,-1.0,tiopronin,"chelating agent, reducing agent",
CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,71,-1.0,gabapentin-enacarbil,adrenergic receptor agonist,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8"
CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)C(=O)NC(Cc1ccc(NC(N)=O)cc1)C(=O)NC(CC(C)C)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O,72,-1.0,degarelix,gonadotropin releasing factor hormone receptor antagonist,GNRHR
CCCCCCCCCCCCCCCCCCOP(=O)(O)OC1CC[N+](C)(C)CC1,73,-1.0,perifosine,AKT inhibitor,AKT1
CCN(CC)C(=O)N[C@H]1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,74,-1.0,terguride,"dopamine receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C"
CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,75,-1.0,buclizine,histamine receptor antagonist,"CHRM1, HRH1"
C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,76,-1.0,citicoline,"membrane permeability enhancer, glutathione transferase stimulant","ACHE, SLC1A2"
OCC(O)COc1ccc(Cl)cc1,77,-1.0,chlorphenesin,muscle relaxant,
Cc1oc(=O)oc1CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)c2n3C(C)S2)CC1,78,-1.0,prulifloxacin,bacterial DNA gyrase inhibitor,
O=C1N=C2SCCN2C(=O)C1Cc1ccc(Cl)cc1,79,-1.0,nuclomedone,immunosuppressant,
C[N+]1(CC2CC2)[C@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21,80,-1.0,cimetropium,acetylcholine receptor antagonist,CHRM1
CCOC(=O)CN1CCN(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)CC1,81,-1.0,cinepazet,vasodilator,
CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1,82,-1.0,brivaracetam,voltage-gated sodium channel blocker,SV2A
COc1ccccc1OC(=O)c1ccccc1OC(C)=O,83,-1.0,guacetisal,immunosuppressant,
C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,84,-1.0,priralfinamide,sodium channel blocker,CACNA1B
O=C(O)[C@@H]1CCCN1,85,-1.0,L-proline,glutamate receptor agonist,"EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7"
Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1,86,-1.0,denotivir,antiviral,
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,87,-1.0,sivelestat,elastase inhibitor,"CELA1, ELANE"
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,88,-1.0,fluorometholone-acetate,,NR3C1
Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1,89,-1.0,PF-05190457,growth hormone secretagogue receptor inverse agonist,GHSR
O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1,90,-1.0,phenylbenzimidazole-sulfonic-acid,,
CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1,91,-1.0,piboserod,serotonin receptor antagonist,"HTR2B, HTR4"
COc1cc2c(N(C)C3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,92,-1.0,UNC0737,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2"
CCCN1C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]2Cc3c(O)cccc3C[C@H]21,93,-1.0,quinagolide,dopamine receptor agonist,DRD2
CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1,94,-1.0,elafibranor,PPAR receptor agonist,"PPARA, PPARD"
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,95,-1.0,ravuconazole,sterol demethylase inhibitor,
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,96,0.676758553,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR"
Cc1ccc(-c2ncccn2)c(C(=O)N2C[C@H](COc3ccc(F)cn3)CC[C@H]2C)c1,97,-1.0,MK-6096,orexin receptor antagonist,"HCRTR1, HCRTR2"
CCNCCCNCCCCNCCCNCC,98,-1.0,"1,12-Besm",polyamine biosynthesis inhibitor,
CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2[C@@H](c2ccccc2)N1,99,-1.0,GSK2330672,bile acid transporter inhibitor,SLC10A2
CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(=O)O)C(=O)NCCCCN=C(N)N,100,-1.0,E-64,"cysteine protease inhibitor, calpain inhibitor",CTSS
CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O,101,-1.0,bremelanotide,melanocortin receptor agonist,"MC1R, MC2R, MC3R, MC4R, MC5R"
CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1,102,-1.0,velneperit,neuropeptide receptor antagonist,NPY5R
C[C@H](Cc1ccc2c(c1)OC(C(=O)O)(C(=O)O)O2)NC[C@H](O)c1cccc(Cl)c1,103,-1.0,CL316243,adrenergic receptor agonist,"ADRB3, UCP1, UCP2, UCP3"
CSCC[C@H](N)C(=O)O,104,-1.0,L-methionine,voltage-gated calcium channel ligand,
CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,105,-1.0,apratastat,"matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9"
FC(F)(F)c1ccc(N2CCNCC2)nc1Cl,106,-1.0,Org-12962,serotonin receptor agonist,"HTR2A, HTR2B, HTR2C"
C#C[C@]1(OC(=O)CCCCCC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,107,-1.0,norethisterone-enanthate,contraceptive agent,
Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,108,-1.0,palosuran,urotensin receptor antagonist,UTS2R
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC(=O)[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1,109,-1.0,7-keto-DHEA,steroid,
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,110,-1.0,frovatriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D"
Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,111,-1.0,YM022,CCK receptor antagonist,CCKBR
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C,112,-1.0,elbasvir,HCV inhibitor,
c1cnc(SCc2cccnc2)nc1,113,-1.0,tasuldine,mucolytic agent,
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN(CC)CC)c1ccccc1S2,114,-1.0,ethacizin,anticonvulsant,
O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1,115,-1.0,niceritrol,NAD precursor,
CC(C)(C)c1ccc(CN(Cc2cccc(OCC(=O)O)c2)S(=O)(=O)c2cccnc2)cc1,116,-1.0,evatanepag,prostaglandin inhibitor,"PTGER2, PTGER4"
O=S(=O)(O)CCCS(=O)(=O)O,117,-1.0,eprodisate,"antiamyloidogenic agent, amyloid protein inhibitor",SAA1
CN1CCN(c2cccc3[nH]c(=O)oc23)CC1,118,0.9166386329999999,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7"
Cc1ncc(-c2csc(NC(=N)N)n2)[nH]1,119,-1.0,zaltidine,histamine receptor antagonist,HRH2
O=C(O)[C@@H](c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1,120,-1.0,veliflapon,leukotriene synthesis inhibitor,ALOX5AP
COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCCN(C(C)C)CC3)nc2cc1OCCCN1CCCCC1,121,0.86782677,UNC0631,histone lysine methyltransferase inhibitor,EHMT2
COC(=O)[C@H]1[C@@H](C)[C@@H](OC)C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C/[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@@H]1C,122,-1.0,rifamycin-sv,RNA synthesis inhibitor,
C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1,123,-1.0,radafaxine,dopamine-norepinephrine reuptake inhibitor,SLC6A3
COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC,124,-1.0,vesnarinone,phosphodiesterase inhibitor,"KCNH2, PDE3A"
CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2c(c1O)CCCC2,125,-1.0,naphthoquine-phosphate,antimalarial agent,
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@@]21C)C(C)C,126,-1.0,daucosterol,apoptosis stimulant,
Cc1nn(C)c2c1C(c1cccc(Cl)c1)=NCCN2,127,-1.0,zometapine,,
CCOc1ccc(/C=C2/NCCc3cc(OCC)c(OCC)cc32)cc1OCC,128,-1.0,drotaverine,phosphodiesterase inhibitor,"CACNA1C, PDE4A"
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,129,-1.0,mupirocin,isoleucyl-tRNA synthetase inhibitor,
CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,130,-1.0,fmoc-l-leucine,PPAR receptor agonist,
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](OS(=O)(=O)O)CC[C@@]43C)[C@@H]1CCC2=O,131,-1.0,dehydroepiandrosterone-sulfate,"androgen receptor agonist, estrogen receptor agonist","AR, ESR1, ESR2"
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,132,-1.0,GSK2190915,lipoxygenase inhibitor,ALOX5AP
Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,133,1.193460164,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1
O=c1nc[nH]c2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,134,1.172184244,forodesine,purinergic receptor antagonist,PNP
COC(=O)c1cc(OC)c2c(c1-c1c(CO)cc(OC)c3c1OCO3)OCO2,135,-1.0,bicyclol,NFkB pathway inhibitor,"HSPA1A, HSPB1"
CC(C)(C)C(=O)CN1C(=O)[C@H](NC(=O)Nc2cccc(C(=O)O)c2)CN(C2CCCCC2)c2ccccc21,136,-1.0,nastorazepide,CCK receptor antagonist,CCKBR
C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1,137,-1.0,delamanid,bacterial cell wall synthesis inhibitor,
CCCCCCCCCCOc1cc2c(O)c(C(=O)OCC)cnc2cc1OCC,138,-1.0,decoquinate,antiprotozoal agent,
CCOCCOC(=O)/C=C/c1ccc(OC)cc1,139,-1.0,cinoxate,,
COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,140,-1.0,melevodopa,"dopamine precursor, dopamine receptor agonist",DDC
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@@](C)(O)C2,141,-1.0,schisandrol-b,lipid peroxidase inhibitor,
O=C(/C=C/c1ccc(O)c2c1[C@@H](C(=O)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O)[C@H](c1ccc(O)c(O)c1)O2)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,142,1.2409596090000001,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9
O=C(O)COc1nn(Cc2ccccc2)c2ccccc12,143,-1.0,bendazac,cyclooxygenase inhibitor,"PTGS1, PTGS2"
CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(Cc1cc(C(=O)O)cs1)C[C@H]2c1ccc(C#N)cc1,144,-1.0,BMS-587101,integrin antagonist,"ITGAL, ITGB2"
COc1cc(C(=O)c2c(C)oc3c(O)c(OC)ccc23)cc(OC)c1OC,145,0.6454791910000001,BNC105,tubulin polymerization inhibitor,
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,146,-1.0,AMG-319,PI3K inhibitor,PIK3CD
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,147,-1.0,selexipag,"platelet aggregation inhibitor, IP1 prostacyclin receptor agonist",PTGIR
C=C(NNC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(C(=C)NNC(=N)N)cc(C(=C)NNC(=N)N)c2)cc(C(=C)NNC(=N)N)c1,148,-1.0,semapimod,"cytokine production inhibitor, p38 MAPK inhibitor",MAPK14
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,149,-1.0,fimasartan,angiotensin receptor antagonist,AGTR1
O=C(CCn1cnc2c(O)ncnc21)Nc1ccc(C(=O)O)cc1,150,-1.0,leteprinim,nerve growth factor agonist,
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,151,0.760705537,napabucasin,STAT inhibitor,STAT3
Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,152,-1.0,EGF816,EGFR inhibitor,EGFR
Cc1cccc(O)c1,153,-1.0,metacresol,,INS
NNC(=O)CN1C(=O)CN=C(c2ccccc2)c2cc(Br)ccc21,154,1.064258294,gidazepam,GABA benzodiazepine site receptor agonist,
Cc1c(CN(C)C(=O)/C=C/C2=CNC3=NC(=O)CCC3=C2)oc2ccccc12,155,-1.0,AFN-1252,FABI inhibitor,
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,156,-1.0,fosaprepitant-dimeglumine,tachykinin antagonist,TACR1
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,157,-1.0,methylprednisolone-aceponate,"anti-inflammatory agent, glucocorticoid receptor agonist",NR3C1
COc1ccc(-c2oc3c(CC=C(C)C)c(O)cc(O)c3c(=O)c2O)cc1,158,-1.0,icaritin,PPAR receptor antagonist,PDE5A
O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2,159,-1.0,setipiprant,prostaglandin inhibitor,PTGDR2
CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2,160,-1.0,amibegron,adrenergic receptor agonist,ADRB3
NS(=O)(=O)NCc1csc2ccccc12,161,-1.0,JNJ-26990990,anticonvulsant,
O=C(Nc1ccc(Cl)cc1)Nc1ccc(Cl)c(Cl)c1,162,-1.0,triclocarban,other antibiotic,
O=C(O)/C=C\c1c[nH]cn1,163,-1.0,cis-urocanic acid,serotonin receptor agonist,HTR2A
O=C(/C=C/c1cccc(F)c1)NC1CC1,164,-1.0,cinflumide,muscle relaxant,
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,165,-1.0,oxytocin,oxytocin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR"
CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1,166,-1.0,chlorproguanil,dihydrofolate reductase inhibitor,DHFR
CCN(CC)c1ccc(-n2nc3cc(C)c(N)cc3n2)cc1,167,-1.0,ezutromid,utrophin enhancer,UTRN
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)C[C@H]3O[C@@]312,168,-1.0,resibufogenin,Na/K-ATPase inhibitor,
CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,169,-1.0,desoxycorticosterone-pivalate,corticosteroid agonist,NR3C2
Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,170,0.8815405635,tucatinib,EGFR inhibitor,ERBB2
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,171,-1.0,leuprolide,gonadotropin releasing factor hormone receptor agonist,GNRHR
O=C(O)c1ccc(SSc2ccc(C(=O)O)cn2)nc1,172,0.996707366,carboxypyridine-disulfide,,
O=C(O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1,173,-1.0,daltroban,thromboxane receptor antagonist,TBXA2R
COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1,174,-1.0,AMG-337,MET inhibitor,MET
O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,175,-1.0,tiaramide,anti-inflammatory agent,
CC/C=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(COC(N)=O)CS[C@H]12)c1csc(N)n1,176,-1.0,cefcapene-pivoxil,bacterial cell wall synthesis inhibitor,
Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,177,-1.0,pleconaril,,
Cc1cnc(NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1,178,-1.0,PF-04937319,glucokinase activator,GCK
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)c1csc(N)n1,179,-1.0,cefetamet,bacterial cell wall synthesis inhibitor,
C[C@@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2(C(=O)O)CC[C@H]1C,180,-1.0,corosolic-acid,"PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1"
CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O,181,0.753248296,beta-lapachone,topoisomerase inhibitor,TOP1
Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,182,0.992253732,chidamide,HDAC inhibitor,"HDAC10, HDAC3"
COc1cc(C(=S)N2CCOCC2)cc(OC)c1OC,183,-1.0,sulmetozine,gastrin inhibitor,GAST
Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,184,-1.0,imidafenacin,acetylcholine receptor antagonist,"CHRM1, CHRM3"
O=C(Nc1ccccc1F)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O,185,-1.0,RSV604,RSV replication inhibitor,
CN[C@@H]1Cc2cccc3nc(O)n(c23)C1,186,-1.0,sumanirole,dopamine receptor agonist,DRD2
CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,187,-1.0,miocamycin,other antibiotic,
CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O,188,-1.0,INT-747,FXR agonist,
COCc1nnc(N2CC(Oc3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,189,-1.0,PF-3274167,oxytocin receptor antagonist,"AVPR1A, OXTR"
Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F,190,-1.0,JNJ-37822681,dopamine receptor antagonist,DRD2
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,191,-1.0,solithromycin,protein synthesis inhibitor,
CCCC(CCC)C(=O)NCC(N)=O,192,-1.0,valrocemide,,
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,193,-1.0,cortodoxone,androgen receptor antagonist,AR
C=C[C@@H]1C2=CCOC(=O)C2=CO[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,194,-1.0,gentiopicrin,glutamate receptor downregulator,GRIN2B
Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,195,-1.0,dapiprazole,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D"
O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1,196,-1.0,flibanserin,serotonin receptor agonist,"DRD4, HTR1A, HTR2A"
c1ccc(C2(c3ccccc3)CC2=C2NCCN2)cc1,197,1.275253235,cibenzoline,sodium channel blocker,
Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,198,-1.0,L-365260,CCK receptor antagonist,"CCKAR, CCKBR, KCNQ1"
O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1,199,-1.0,CHF5074,gamma secretase modulator,PSEN1
Cc1[nH]c2ccccc2c1C[C@@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,200,-1.0,examorelin,growth hormone releasing factor agonist,"GHRHR, GHSR"
COc1ccc(/C=C/CCCCOc2ccc(C(=O)c3cccc(C(=O)O)c3)cc2CCC(=O)O)cc1,201,-1.0,LY223982,leukotriene receptor antagonist,LTB4R
COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,202,-1.0,TRV130,opioid receptor agonist,OPRM1
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,203,-1.0,polidocanol,local anesthetic,
O=C(O)Cc1cccc2c(=O)cc(-c3ccccc3)oc12,204,-1.0,mitoflaxone,antitumor agent,VWF
Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O,205,-1.0,OC000459,CRTH receptor antagonist,PTGDR2
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,206,-1.0,paromomycin,bacterial 30S ribosomal subunit inhibitor,
O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1,207,-1.0,LOXO-101,tropomyosin receptor kinase inhibitor,"NTRK1, NTRK2, NTRK3"
Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1,208,-1.0,nolatrexed,thymidylate synthase inhibitor,TYMS
CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O,209,-1.0,verinurad,urate transporter inhibitor,SLC22A12
CCOc1cc(OCC)c(C(=O)CCC(=O)O)cc1OCC,210,-1.0,trepibutone,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4"
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1,211,-1.0,exisulind,phosphodiesterase inhibitor,PDE5A
N#Cc1ccc(N(Cc2ccc(Br)cc2)n2cnnc2)cc1,212,-1.0,YM-511,aromatase inhibitor,CYP19A1
CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,213,-1.0,droloxifene,selective estrogen receptor modulator (SERM),ESR1
CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,214,0.908751438,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3"
O=C1CCC2CCC(=O)N12,215,-1.0,rolziracetam,,
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,216,-1.0,entrectinib,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor","ALK, NTRK1, NTRK2, NTRK3, ROS1"
COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,217,-1.0,eluxadoline,opioid receptor modulator,"OPRD1, OPRK1, OPRM1"
O=C1c2cccnc2OC[C@@H]2CCCN12,218,-1.0,org-26576,glutamate receptor modulator,
Cc1ccc(=O)n(-c2ccc(O)cc2)c1,219,-1.0,F351,TGF beta receptor inhibitor,TGFB1
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,220,-1.0,naloxegol,opioid receptor antagonist,OPRM1
COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1,221,-1.0,tecalcet,calcium-sensing receptor agonist,CASR
CC(=O)N(C)c1cc(-c2ccnc3c(C(=O)c4cccs4)cnn23)ccc1F,222,-1.0,lorediplon,GABA receptor modulator,GABRA1
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,223,-1.0,alarelin,gonadotropin releasing factor hormone receptor antagonist,GNRH1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC,224,-1.0,norelgestromin,,PGR
COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,225,0.508452514,verubulin,tubulin polymerization inhibitor,TUBB
CC(C)N[C@H]1CCn2c(O)nc3cccc(c32)[C@@H]1O,226,-1.0,zilpaterol,adrenergic receptor agonist,ADRB2
FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,227,-1.0,MK-2295,TRPV antagonist,TRPV1
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,228,-1.0,hemoglobin-modulators-1,hemoglobin modulator,
Cc1oncc1C(=O)N1CCCCC1,229,-1.0,nerbacadol,cyclooxygenase inhibitor,
N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,230,-1.0,pruvanserin,serotonin receptor antagonist,"HTR2A, HTR2C"
CC(C)(CO)CCCCCCC(C)(C)CO,231,-1.0,gemcadiol,antilipemic,
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,232,-1.0,ponesimod,sphingosine 1 phosphate receptor agonist,S1PR1
O=C(N[C@H]1CN2CCC1CC2)c1cnc2ccsc2c1O,233,-1.0,pumosetrag,serotonin receptor agonist,"HTR3A, HTR4"
OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,234,-1.0,ospemifene,selective estrogen receptor modulator (SERM),"ESR1, ESR2"
COC(=O)C1=C(C)N(C)C(C)=C(C(=O)OC)C1c1ccc(C(F)(F)F)cc1,235,-1.0,bay-w-9798,antioxidant,
CS(=O)(=O)c1ccc(-c2cn3ccccc3n2)cc1,236,-1.0,zolimidine,mucus protecting agent,
Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,237,-1.0,presatovir,RSV fusion inhibitor,
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N,238,-1.0,ozanimod,sphingosine 1 phosphate receptor agonist,S1PR1
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,239,-1.0,zotarolimus,mTOR inhibitor,FKBP1A
CCN(Cc1ccc(Cl)nc1)/C(=C/[N+](=O)[O-])NC,240,-1.0,nitenpyram,,
CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,241,-1.0,pipotiazine-palmitate,"dopamine receptor antagonist, serotonin receptor antagonist","DRD1, DRD2, HTR1A, HTR2A"
Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1,242,-1.0,SRT2104,SIRT activator,SIRT1
COc1ccc2c(c1)C=C1Cn3c-2c(C2CCCCC2)c2ccc(cc23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O,243,-1.0,TMC647055,RNA polymerase inhibitor,
CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,244,-1.0,caspofungin-acetate,"fungal 1,3-beta-D-glucan synthase inhibitor",
CCn1cc(C(=O)O)c(=O)c2ccc(-c3ccncc3)cc21,245,-1.0,rosoxacin,topoisomerase inhibitor,
C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,246,0.6623235435,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4"
N[C@@H](Cc1ccc(B(O)O)cc1)C(=O)O,247,-1.0,boronophenylalanine,,
CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,248,-1.0,alacepril,angiotensin converting enzyme inhibitor,ACE
CCCCc1nc(-c2ccc(OCCCN(CC)CC)cc2)cn1-c1ccc(Oc2ccc(Cl)cc2)cc1,249,-1.0,azeliragon,RAGE receptor antagonist,AGER
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)O)c1I,250,-1.0,iopodic-acid,,
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,251,-1.0,TGR-1202,PI3K inhibitor,
C#Cc1cncc([C@@H]2CCCN2C)c1,252,-1.0,altinicline,nicotinic receptor agonist,"CHRNA4, CHRNB2"
N=C(Nc1ccccc1)c1cccs1,253,-1.0,LTA,,
CN1CCN(c2ncc(-c3cc(Cl)cc(Cl)c3Cl)c(N)n2)CC1,254,-1.0,sipatrigine,voltage-gated sodium channel blocker,"CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A"
CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,255,-1.0,aprindine,voltage-gated sodium channel blocker,"CALM1, SCN5A"
CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,256,-1.0,estradiol-acetate,estrogen receptor agonist,ESR1
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,257,-1.0,fosphenytoin,sodium channel blocker,SCN5A
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,258,-1.0,pexidartinib,tyrosine kinase inhibitor,"CSF1R, FLT3, KIT"
CC(=O)O[C@@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4[C@@H](C)[C@H](C)CC[C@]4(C)CC[C@]23C)[C@@]1(C)C(=O)O,259,-1.0,AKBA,lipoxygenase inhibitor,ALOX5
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,260,0.866067868,niraparib,PARP inhibitor,PARP1
CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O,261,-1.0,JNJ-40411813,glutamate receptor positive allosteric modulator,GRM2
Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,262,-1.0,apricitabine,nucleoside reverse transcriptase inhibitor,
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,263,-1.0,elagolix,gonadotropin releasing factor hormone receptor antagonist,GNRHR
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,264,-1.0,alcaftadine,histamine receptor antagonist,HRH1
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,265,-1.0,carbetocin,oxytocin receptor agonist,OXTR
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,266,-1.0,ergocalciferol,vitamin analog,VDR
CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,267,-1.0,RTA-408,nitric oxide production inhibitor,NFE2L2
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](O)C2CC2)C[C@@H](O)C[C@@H]1O,268,-1.0,calcipotriol,vitamin D receptor agonist,VDR
COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,269,-1.0,flindokalner,potassium channel agonist,"KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5"
O=C(O)CNC(=O)c1nc(Cl)c2ccccc2c1O,270,-1.0,FG-2216,hypoxia inducible factor prolyl hydroxylase inhibitor,"EGLN1, EGLN2, HIF1A"
O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,271,-1.0,SAR407899,rho associated kinase inhibitor,ROCK1
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,272,0.827771723,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR"
COc1cn(-c2ccc(-n3cccn3)cc2F)nc(-c2ccnn2-c2ccccc2)c1=O,273,-1.0,TAK-063,phosphodiesterase inhibitor,PDE10A
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,274,-1.0,NPC-01,steroid,
Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,275,1.0780251405,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10
CCCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@@]21C,276,-1.0,clobetasone-butyrate,corticosteroid agonist,NR3C1
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O,277,0.9953173679999999,cyclovalone,breast cancer resistance protein inhibitor,ABCG2
CCN(CC)CCOC(=O)C1(c2ccccc2)CCCC1,278,-1.0,caramiphen,cholinergic receptor antagonist,"CHRM1, CHRM2"
O=C(O)CCCN1C(=O)c2cccc3cccc(c23)C1=O,279,-1.0,isodibut,aldehyde reductase inhibitor,
Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1,280,-1.0,titanocene-dichloride,apoptosis stimulant,
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,281,-1.0,olmutinib,"EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor","BTK, EGFR"
c1ccc(CCNc2nc(-c3ccccc3)cs2)cc1,282,-1.0,fanetizole,neutrophil superoxide production,
OC[C@H]1NCC[C@@H](O)[C@@H]1O,283,-1.0,fagomine,glucosidase inhibitor,GLB1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,284,-1.0,GDC-0810,selective estrogen receptor destabilizer,ESR1
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN1CCCC1,285,-1.0,toceranib,protein tyrosine kinase inhibitor,"FLT1, FLT3, KDR, PDGFRA, PDGFRB"
CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,286,-1.0,grapiprant,prostaglandin inhibitor,PTGER4
C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2,287,-1.0,huperzine-a,acetylcholinesterase inhibitor,ACHE
Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,288,0.734287241,PI3K-IN-2,PI3K inhibitor,
CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1,289,-1.0,siponimod,sphingosine phosphate receptor modulator,S1PR1
CCOP(=O)(Cc1ccc(C(=O)Nc2ccc(Br)cc2C#N)cc1)OCC,290,-1.0,ibrolipim,lipoprotein lipase activator,LPL
CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2,291,-1.0,tasimelteon,melatonin receptor agonist,"MTNR1A, MTNR1B"
O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,292,-1.0,relebactam,beta lactamase inhibitor,
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,293,-1.0,ETC-1002,AMPK inhibitor,ACLY
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,294,-1.0,icatibant-acetate,bradykinin receptor antagonist,"ANPEP, BDKRB2"
CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(CCc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,295,0.750631565,vinflunine,microtubule inhibitor,
Cc1ccc(-c2ccc(C)cn2)nc1,296,-1.0,abametapir,metalloproteinase inhibitor,MMP9
CCN(CC)CCN1C(=O)C(=Cc2ccc(OC)cc2)Nc2ccccc21,297,-1.0,caroverine,"glutamate receptor antagonist, calcium channel blocker",
Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1,298,-1.0,opicapone,catechol O methyltransferase inhibitor,COMT
COc1cc(/C=C/C(=O)O)ccc1O,299,-1.0,ferulic-acid,antioxidant,"CA1, CA12, CA14, CA2, CA4, CA6, CA9"
CCc1oc2ccccc2c1C(=O)c1ccc(OCC(=O)O)cc1,300,-1.0,KT-433,uricosuric agent,
CC(C)C[C@H](CN)CC(=O)O,301,-1.0,pregabalin,voltage-gated calcium channel ligand,"CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8"
O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,302,-1.0,sophocarpine,,
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,303,-1.0,dextran,,
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,304,-1.0,itacitinib,JAK inhibitor,JAK1
NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,305,1.316018885,carboxyamidotriazole,calcium channel blocker,CXCL8
O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,306,-1.0,avatrombopag,thrombopoietin receptor agonist,MPL
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,307,-1.0,pantethine,coenzyme A precursor,
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CCC(=O)O2,308,-1.0,testolactone,aromatase inhibitor,CYP19A1
Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,309,-1.0,GSK163090,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D"
CCc1ccc(C2=CC(C)(C)Sc3ccc(C#Cc4ccc(C(=O)O)cc4)cc32)cc1,310,-1.0,AGN-194310,retinoid receptor antagonist,"RXRA, RXRB, RXRG"
O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,311,-1.0,JNJ-42165279,FAAH inhibitor,FAAH
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,312,-1.0,fruquintinib,VEGFR inhibitor,KDR
NC(=O)OC[C@@H]1[C@H](NC(=O)/C(=N\OCC(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,313,-1.0,carumonam,bacterial cell wall synthesis inhibitor,
CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,314,0.924425497,gilteritinib,FLT3 inhibitor,FLT3
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,315,1.278008124,etoposide-phosphate,topoisomerase inhibitor,TOP2A
COc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1,316,-1.0,oxyfedrine,adrenergic receptor agonist,
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,317,-1.0,vasopressin,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2, OXTR"
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1,318,-1.0,pyronaridine,antimalarial agent,
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,319,-1.0,terlipressin,vasopressin receptor agonist,"AVPR1A, AVPR1B, AVPR2"
[2H]N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC,320,-1.0,bivalirudin,thrombin inhibitor,F2
CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,321,-1.0,GS-9620,toll-like receptor agonist,TLR7
CCCCCCOC(=O)CCC(=O)CN,322,0.958244344,hexaminolevulinate,,
Oc1ccc(C2=Cc3ccc(O)cc3OC2)cc1,323,1.289389593,idronoxil,XIAP inhibitor,"ENOX2, SPHK1"
CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN)OC[C@]1(C)O,324,-1.0,isepamicin,protein synthesis inhibitor,
CC(C)N(CCc1c[nH]c2ccccc12)C(C)C,325,-1.0,DIPT,"dopamine reuptake inhibitor, serotonin reuptake inhibitor","HTR1A, HTR2A, HTR2C"
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,326,-1.0,estetrol,selective estrogen receptor modulator (SERM),ESR1
Cc1ncc(CO)c(C=O)c1O,327,-1.0,pyridoxal,,PDXK
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,328,-1.0,cetrorelix,gonadotropin releasing factor hormone receptor antagonist,"GNRHR, LHCGR"
COc1ccc(C(C)(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,329,-1.0,maropitant,neurokinin receptor antagonist,TACR1
OB1OCc2cc(F)ccc21,330,-1.0,tavaborole,leucyl-tRNA synthetase inhibitor,
O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1,331,-1.0,nitrofurantoin,DNA inhibitor,
C[C@H]1NCc2cc(-c3ccc4c(=O)c(C(=O)O)cn(C5CC5)c4c3OC(F)F)ccc21,332,-1.0,garenoxacin,topoisomerase inhibitor,TOP2A
CO[C@@]1(NC(=O)CSC[C@@H](N)C(=O)O)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,333,-1.0,cefminox,bacterial cell wall synthesis inhibitor,
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,334,-1.0,calcifediol,vitamin D receptor agonist,VDR
COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O,335,-1.0,secoisolariciresinol-diglucoside,antioxidant,
COc1cc2c(NC3CCN(C)CC3)nc(N3CCCN(C)CC3)nc2cc1OCCCN(C)C,336,-1.0,UNC0224,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2"
Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1,337,-1.0,abafungin,sterol methyltransferase inhibitor,
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21,338,-1.0,fenoverine,acetylcholine receptor antagonist,
Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,339,-1.0,lemborexant,orexin receptor antagonist,"HCRTR1, HCRTR2"
COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(=O)O,340,-1.0,aspartame,,"TAS1R2, TRPV1"
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,341,-1.0,INCB-024360,"indoleamine 2,3-dioxygenase inhibitor",IDO1
CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1,342,-1.0,GKT137831,NADPH oxidase inhibitor,"NOX1, NOX4"
Cc1ncccc1OC[C@@H]1CCCN1,343,-1.0,pozanicline,acetylcholine receptor antagonist,"CHRNA4, CHRNB2"
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,344,0.28717944300000003,rubitecan,topoisomerase inhibitor,TOP1
O=C1c2ccccc2CN2C(=O)c3ccccc3CN12,345,-1.0,diftalone,cyclooxygenase inhibitor,
CC(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1,346,-1.0,FK-962,somatostatin receptor agonist,
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,347,-1.0,resveratrol,"cytochrome P450 inhibitor, SIRT activator","CSNK2A1, NQO2, PTGS1, PTGS2"
CC1(C)C(/C=C/C=C/C=C/C=C2/N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,348,-1.0,indocyanine-green,contrast agent,SLCO1B1
CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,349,-1.0,haloperidol-decanoate,psychoactive drug,"DRD2, DRD3, DRD4, HTR2A"
CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O,350,-1.0,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF"
CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(c2ccc(C(N)=O)cc2)CC1,351,-1.0,PNU-142633,serotonin receptor agonist,HTR1D
O=C(/C=C/c1c(C(=O)O)[nH]c2cc(Cl)cc(Cl)c12)Nc1ccccc1,352,-1.0,gavestinel,glutamate receptor antagonist,GLRB
NNc1nncc2ccccc12,353,-1.0,hydralazine,vasodilator,"AOC3, P4HA1"
O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,354,-1.0,pyrantel,nicotinic receptor agonist,
Cc1ccc(NC2=NCCN2)c(Cl)c1,355,-1.0,tolonidine,adrenergic receptor antagonist,ADRA2A
Cc1oc(-c2ccccc2)nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1,356,-1.0,darglitazone,PPAR receptor antagonist,PPARG
CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,357,0.72239792,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR
CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C,358,0.8338627075,litronesib,kinesin-like spindle protein inhibitor,KIF11
C[n+]1ccccc1/C=N/O,359,-1.0,pralidoxime,acetylcholinesterase inhibitor,"ACHE, BCHE"
O=C(O)C=C1NN(Cc2nc3cc(C(F)(F)F)ccc3s2)C(=O)c2ccccc21,360,-1.0,zopolrestat,,
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,361,-1.0,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4"
NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,362,-1.0,avibactam,beta lactamase inhibitor,
c1cc2c(c(N3CCNCC3)c1)OCCO2,363,-1.0,eltoprazine,serotonin receptor agonist,"HTR1A, HTR1B"
Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1,364,-1.0,bromantan,"dopamine reuptake inhibitor, serotonin reuptake inhibitor",
CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2,365,-1.0,eliglustat,Glycosyl transferase inhibitor,UGCG
CC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,366,-1.0,sutezolid,protein synthesis inhibitor,
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,367,-1.0,chloroprocaine,sodium channel blocker,"ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3"
C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12,368,-1.0,prinaberel,estrogen receptor agonist,"ESR2, NCOA1"
COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O,369,-1.0,diroximel-fumarate,anti-inflammatory agent,
N#CCC(=O)c1ccccc1,370,-1.0,CL-225385,,
NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3,371,-1.0,irosustat,steroid sulfatase inhibitor,"CA2, STS"
Cn1c(=O)cnn(CCCCN2CCN(c3ncccn3)CC2)c1=O,372,-1.0,F-11440,serotonin receptor agonist,HTR1A
O=C(O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1,373,-1.0,taprenepag,prostaglandin receptor agonist,PTGER2
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,374,1.145965152,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1,375,0.8649755490000001,tedizolid-phosphate,protein synthesis inhibitor,
CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,376,-1.0,nalfurafine,opioid receptor agonist,"OPRK1, OPRM1"
Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,377,-1.0,paritaprevir,HCV inhibitor,
CC(C)CC(N)=O,378,-1.0,isovaleramide,alcohol dehydrogenase inhibitor,
CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,379,-1.0,LY2452473,androgen receptor modulator,AR
C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O,380,-1.0,natamycin,fungal ergosterol inhibitor,
CCOc1c(N2CCOCC2)cnn(C)c1=O,381,-1.0,emorfazone,"antiinflammatory agent, cyclooxygenase inhibitor",
CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,382,-1.0,etilevodopa,dopamine receptor agonist,DRD3
CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,383,-1.0,propiverine,acetylcholine receptor antagonist,CHRM1
C1Cc2[nH]nc(-c3nnn[nH]3)c2C1,384,-1.0,MK-0354,niacin receptor agonist,"HCAR2, HCAR3"
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,385,1.338636203,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA
O=C(CN1CCNCC1)NC1CCCCC1,386,-1.0,esaprazole,,
O=C(c1ccccn1)c1cnn2c(-c3ccncc3)ccnc12,387,-1.0,ocinaplon,GABA receptor modulator,"GABRA1, GABRA2, GABRA3, GABRA5"
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,388,-1.0,hydroxyprogesterone-acetate,progesterone receptor agonist,PGR
CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O,389,-1.0,medica-16,ATP citrase lyase inhibitor,FFAR1
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1,390,-1.0,vorapaxar,thrombin receptor antagonist,F2R
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C,391,-1.0,stetaderm,,
O=C(NO)c1ccc(O)c(O)c1,392,-1.0,didox,ribonucleotide reductase inhibitor,RRM1
CN1C(=O)N(C[C@H](C(=O)NO)[C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)C1(C)C,393,-1.0,cipemastat,metalloproteinase inhibitor,"ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9"
O=C1CNC(=O)CN1,394,-1.0,piperazinedione,DNA synthesis inhibitor,
O=C(Cc1ccc(-c2ccccc2)cc1)Nc1ccccn1,395,-1.0,difenpiramide,"cyclooxygenase inhibitor, prostaglandin inhibitor",
Cc1ncc(CO)c(CN)c1O,396,-1.0,pyridoxamine,AGE inhibitor,
Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,397,-1.0,mebrofenin,,
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,398,-1.0,ceftriaxone,bacterial cell wall synthesis inhibitor,
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,399,-1.0,gonadorelin,gonadotropin releasing factor hormone receptor agonist,"GNRHR, GNRHR2"
O=C(O)Cn1c2ccccc2c(=O)c2ccccc21,400,-1.0,cridanimod,progesterone receptor agonist,PGR
CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1,401,-1.0,epalrestat,aldose reductase inhibitor,AKR1B1
Cn1nc(-c2cccc(F)c2)n(C)c1=S,402,-1.0,suritozole,GABA receptor inverse agonist,GABBR1
O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1,403,-1.0,befuraline,,
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,404,-1.0,hydrocortisone-butyrate,glucocorticoid receptor agonist,NR3C1
CC(C)=CCC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(=O)O,405,-1.0,peretinoin,retinoid receptor agonist,RXRA
O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1,406,-1.0,xenalipin,,
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,407,0.9683125309999999,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@]4(C)[C@H]5C[C@@H](O)[C@]6(C)[C@@H](C7=CC(=O)OC7)CC[C@]6(O)[C@@H]5CC[C@@H]4C3)O[C@@H]2C)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](C)O1,408,-1.0,deslanoside,Na/K-ATPase inhibitor,"ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2"
CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,409,-1.0,azelnidipine,calcium channel blocker,CACNA1C
CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,410,-1.0,hydroxypropyl-beta-cyclodextrin,,
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,411,1.162194776,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO,412,0.907337527,betamethasone,glucocorticoid receptor agonist,NR3C1
COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1,413,-1.0,cilnidipine,calcium channel blocker,CACNA1B
O=C(O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(=O)O)C(=O)O1)C(=O)O,414,-1.0,bismuth-subcitrate-potassium,,
CC12CCC(C(=O)N(CCCCN3CCN(c4ccccn4)CC3)C1=O)C2(C)C,415,-1.0,piricapiron,"dopamine receptor antagonist, serotonin receptor antagonist",HTR2A
CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1,416,-1.0,eperisone,acetylcholine receptor antagonist,CYP2J2
C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O,417,-1.0,trilostane,3beta-hydroxy-delta5-steroid dehydrogenase inhibitor,"ESR1, ESR2, HSD3B1, HSD3B2"
CC(SC(=O)c1cccs1)C(=O)NCC(=O)O,418,-1.0,stepronin,mucolytic agent,
O=C(O)CSCC(=O)NC1CCSC1=O,419,-1.0,erdosteine,mucolytic agent,
CC1(O)CCOC(=O)C1,420,-1.0,"mevalonic-d,-l-acid-lactone",,
CCOC(=O)C12CC1/C(=N\O)c1ccccc1O2,421,-1.0,CPCCOEt,glutamate receptor antagonist,GRM1
CCN1C[C@]2(OC(=O)c3ccccc3NC(C)=O)CC[C@@H](OC)[C@]34C1[C@@H](C[C@H]23)[C@@]1(O)C[C@H](OC)[C@H]2C[C@H]4[C@]1(O)[C@H]2OC,422,0.879672789,lappaconite,sodium channel blocker,
CC[C@@]1(C2O[C@@H](C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)C[C@@H]2C)CC[C@H]([C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(=O)O)O3)O2)O1,423,0.779602649,monensin,bacterial permeability inducer,
CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C,424,-1.0,anisotropine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3"
CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)C3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(/CCC=C(C)C)C(=O)O,425,-1.0,fusidic-acid,bacterial 30S ribosomal subunit inhibitor,
CC(C)(C)NCC(O)c1ccc(O)cc1Cl,426,-1.0,meluadrine,,
C=C1c2c(Cl)ccc(O)c2C(=O)C2C(=O)[C@]3(O)C(=O)C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12,427,-1.0,meclocycline-sulfosalicylate,bacterial 50S ribosomal subunit inhibitor,
CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1,428,-1.0,buparvaquone,antiprotozoal agent,
OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O,429,-1.0,CDBA,,
C#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4C3C(=C)CC21CC,430,-1.0,etonogestrel,progesterone receptor agonist,"ESR1, PGR"
O=C1/C(=C/c2ccccc2)C(NC2CCCCC2)c2ccccc21,431,0.8863599679999999,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I,432,-1.0,ioxilan,radiopaque medium,
Nc1ncnc2c1nc(Br)n2[C@@H]1O[C@@H]2COP(=O)(O)O[C@H]2[C@H]1O,433,-1.0,8-bromo-cAMP,PKA activator,
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,434,-1.0,boceprevir,HCV inhibitor,"CMA1, CTSA, CTSF, CTSK, CTSL, CTSS"
Nc1ncnc2c1ncn2C1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O,435,-1.0,adenosine-phosphate,adenosine receptor agonist,"ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4"
C[C@@H]1O[C@@H]1P(=O)(O)O,436,-1.0,fosfomycin,bacterial cell wall synthesis inhibitor,
CN1C2=CC(=O)/C(=N\NC(N)=O)C=C2CC1S(=O)(=O)O,437,-1.0,carbazochrome,,
CC(CCC(=O)O)[C@H]1CCC2C3C(=O)C[C@@H]4CC(=O)CC[C@]4(C)C3CC(=O)[C@@]21C,438,1.2041252390000001,dehydrocholate-acid,,
C#CC(C)(O)CC,439,-1.0,meparfylon,,
NC(CC(F)C(=O)O)C(=O)O,440,-1.0,BAY-85-8050,,
C[C@@H]1O[C@@H](O[C@@H]2C=C3CCC4C(CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)C(O)C(O)[C@H]1O,441,0.335193036,proscillaridin-a,,
CO/N=C(/C(=O)NC1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CSC12)c1csc(N)n1,442,-1.0,cefepime,bacterial cell wall synthesis inhibitor,
CC(=O)c1c(O)c(C)c(O)c2c1OC1=CC(=O)C(C(C)=O)C(=O)[C@@]12C,443,1.23341821,usniacin-(+),MAP kinase activator,PTPN1
O=C(O)C1CC(O)CN1,444,-1.0,L-Hydroxyproline,,
NCCCC(N)C(=O)O,445,1.28864867,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4"
O[C@@H]1[C@@H](CCl)O[C@@H](n2cnc3c(NC4CC5CCC4C5)ncnc32)[C@@H]1O,446,-1.0,5'-Chloro-5'-deoxy-ENBA-(+/-),adenosine receptor agonist,ADORA1
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)=O)cc1,447,-1.0,sulindac,cyclooxygenase inhibitor,"AKR1B1, MAPK3, PPARD, PTGDR2, PTGS1, PTGS2"
CCOC(=O)C1CSC(Cc2ccc(OCc3ccc([N+](=O)[O-])cc3)cc2)N1,448,-1.0,SN-6,sodium/calcium exchange inhibitor,
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C(O)C2O)C(O)C1O,449,-1.0,diadenosine-tetraphosphate,adenosine kinase inhibitor,"P2RY13, P2RY2"
N[C@@H](CSSC[C@H](N)C(=O)O)C(=O)O,450,-1.0,L-Cystine,,"CTNS, SLC3A1, SLC7A11, SLC7A9"
CO[C@H]1CC(O[C@@H]2/C(C)=C/C[C@@H]3C[C@@H](C[C@]4(C=C[C@H](C)[C@@H](C5CCCCC5)O4)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC/C(=C\C=C\[C@@H]2C)[C@@]34O)O[C@@H](C)C1O[C@H]1C[C@H](OC)[C@@H](O)[C@H](C)O1,451,-1.0,doramectin,,
C#C[C@]1(O)CCC2C3CCc4cc(OC5CCCC5)ccc4C3CC[C@@]21C,452,-1.0,quinestrol,estrogen receptor agonist,ESR1
CC(=O)C1C(=O)C=C(C)OC1=O,453,-1.0,dehydroacetic-acid,,
CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,454,-1.0,alclometasone-dipropionate,glucocorticoid receptor agonist,"CYP3A4, NR3C1, SERPINA6"
CC(=O)OC(C)C[N+](C)(C)C,455,-1.0,methacholine,acetylcholine receptor agonist,"CHRM2, CHRM3, CHRM4"
CC(C)[C@@H]1C2CCC(C2)[C@H]1N,456,-1.0,AGN-192403,imidazoline receptor ligand,NISCH
COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,457,-1.0,bevantolol,adrenergic receptor antagonist,"ADRA1A, ADRB1, ADRB2"
O=C(O)CC(O)C(=O)O,458,-1.0,malic-acid,,"CS, ME2, PKD2L1"
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,459,-1.0,cyanocobalamin,"methylmalonyl CoA mutase stimulant, vitamin B","MMAA, MMACHC, MTHFR, MTR, MTRR, MUT"
CCCCCC(C)N,460,-1.0,tuaminoheptane,,
FC(F)(F)C(Cl)Br,461,-1.0,halothane,glutamate receptor antagonist,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GNG2, GRIN2A, GRIN3A, GRIN3B, KCNJ3, KCNJ6, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9, KCNMA1, KCNN4, MT-ND1, NPSR1, RHO"
CC(=O)O[C@H]1CC[C@@]2(C)C(=CCC3C4CCC(=O)[C@@]4(C)CCC32)C1,462,-1.0,prasterone-acetate,,
NC(Cc1ccc(O)cc1)C(=O)O,463,-1.0,plovamer-acetate,,"TAT, TH, YARS, YARS2"
CO/N=C(/C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CSC12)c1csc(N)n1,464,-1.0,cefmenoxime,bacterial cell wall synthesis inhibitor,
CC1CCCC(C)N1,465,-1.0,"2,6-dimethylpiperidine",,
C=CC(C)(O)CC[C@@H]1[C@@]2(C)CCCC(C)(C)C2CC[C@@]1(C)O,466,-1.0,sclareol,,
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,467,0.9162370440000001,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3"
CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](OC3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,468,-1.0,troleandomycin,protein synthesis inhibitor,
CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)[C@H](C)C[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)(C4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C,469,0.842027679,narasin,antiprotozoal agent,
N[C@@H](CS(=O)O)C(=O)O,470,-1.0,L-Cysteinesulfinic-acid,glutamate receptor agonist,"GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2"
CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,471,-1.0,ergonovine,"adrenergic receptor agonist, serotonin receptor agonist","ADRA1A, HTR1E"
CCCCC(CC)C/N=C(\N)N/C(N)=N/CCCCCC/N=C(\N)N/C(N)=N/CC(CC)CCCC,472,0.858014488,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1
CC(C)(C)NCC(O)CSc1nc(-c2ccc(C(N)=O)s2)cs1,473,-1.0,arotinolol,adrenergic receptor antagonist,ADRB3
CC[C@@H](C(=O)O)C1CC[C@H](C)C([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)(C5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)O1,474,0.862178159,salinomycin,,
CC(N)(C(=O)O)c1ccc(-c2nnn[nH]2)cc1,475,0.911693231,MTPG,glutamate receptor antagonist,"GRM2, GRM3"
CC(C)NCC(O)c1ccccc1Cl,476,-1.0,clorprenaline,adrenergic receptor agonist,"ADRB1, ADRB2"
CC1(C)C2CC[C@]3(C)[C@H](C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@]43C)[C@@]2(C)CC[C@@H]1OC(=O)CCC(=O)O,477,-1.0,carbenoxolone,11-beta hydroxysteroid dehydrogenase inhibitor,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3"
Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1,478,-1.0,proxodolol,adrenergic receptor antagonist,
CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC,479,-1.0,edelfosine,phospholipase inhibitor,
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(C(=O)O)CC(O)C(NC(C)=O)C(C(O)C(O)CO)O3)C2O)C(O)C1O)NC(=O)CCCCCCCCCCCCCCCCC,480,-1.0,ganglioside-gm1,,
CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO,481,-1.0,monostearin,,
FC(F)OC(Cl)C(F)(F)F,482,-1.0,isoflurane,inhaled anaesthetic,"ATP2C1, ATP5D, CALM1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9"
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,483,-1.0,adenosine-triphosphate,adenosine receptor agonist,"ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7"
CCOC(=O)CSCCC1NC(C(=O)O)CS1,484,-1.0,letosteine,mucolytic agent,
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,485,-1.0,sarpogrelate,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C"
Cc1onc(O)c1CC(N)C(=O)O,486,-1.0,AMPA-(RS),glutamate receptor agonist,GRIN1
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)COP(=O)(O)OCC[N+](C)(C)C,487,-1.0,sphingosylphosphorylcholine,gene expression stimulant,GPR12
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,488,0.660596367,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B"
CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1,489,-1.0,troventol,,
COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)/C=C(\C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,490,0.582711702,bruceantin,protein synthesis inhibitor,
CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,491,1.338710656,colistin-b-sulfate,bacterial permeability inducer,
O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1,492,-1.0,NTNCB,neuropeptide receptor antagonist,NPY5R
NCC(O)CC(=O)O,493,-1.0,aminohydroxybutyric-acid,,
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN,494,-1.0,gemifloxacin,bacterial DNA gyrase inhibitor,
CC(C)Cc1ccc(C(C)C(=O)NO)cc1,495,-1.0,ibuproxam,"cyclooxygenase inhibitor, prostaglandin inhibitor",ALOX5
CC(=O)OC1CC2CCC1(C)C2(C)C,496,-1.0,bornyl-acetate,,
CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]23C(=O)O[C@@H]2OC(=O)[C@H](O)C231,497,-1.0,bilobalide,GABA receptor modulator,"GLRA1, GLRA2, GLRB, HTR3A, HTR3B"
CC(=O)[C@@]12OC(C)(c3ccccc3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]12C,498,-1.0,algestone-acetophenide,,
C=C1CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O,499,0.8893970999999999,melengestrol-acetate,progesterone receptor agonist,
C=CC(C)(O)CCC=C(C)C,500,1.135739749,linalool,anticonvulsant,
O=C(O)CC(S)C(=O)O,501,-1.0,mercaptosuccinic-acid,,
C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O,502,-1.0,3-alpha-Hydroxy-5-beta-androstan-17-one,,
CC(N/C(=N/C#N)Nc1ccncc1)C(C)(C)C,503,-1.0,pinacidil,"ATP channel activator, potassium channel activator","ABCC8, ABCC9"
CC1=C(C(=O)OC2CCCCC2)C(c2ccc([N+](=O)[O-])cc2)C2=C(CC(C)(C)CC2=O)N1,504,0.992531405,FLI-06,notch signaling inhibitor,
CC(=O)O[C@@H]1CC[C@@]2(C)C(CC[C@]3(C)C2C(=O)C=C2[C@@H]4[C@@H](C)[C@H](C)CC[C@]4(C)CC[C@]23C)[C@@]1(C)C(=O)O,505,-1.0,acetyl-11-keto-beta-boswellic-acid,lipoxygenase inhibitor,"HSD11B1, HSD11B2"
CC(=O)OCC1=C2C(=O)O[Zn]OC(=O)C(N)CCCC(=O)N[C@@H]3C(=O)N2C3SC1,506,-1.0,cephalosporin-c-zn,bacterial cell wall synthesis inhibitor,
C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12,507,-1.0,methylprednisolone-sodium-succinate,glucocorticoid receptor agonist,
O=C(/C=C/c1ccccc1)NC(NC(=S)Nc1cccc2cccnc12)C(Cl)(Cl)Cl,508,-1.0,salubrinal,eukaryotic translation initiation factor inhibitor,EIF2S1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(O)CCc1ccccc1,509,-1.0,bimatoprost,prostanoid receptor agonist,"AKR1C3, PTGER1, PTGER3, PTGFR"
O=C(/C=C/c1ccccc1)NC(NC(=S)Nc1ccc(Cl)cc1)C(Cl)(Cl)Cl,510,-1.0,sal003,eukaryotic translation initiation factor inhibitor,EIF2A
O=C(O)c1ccc(NC2OC(CO)C(O)C(O)C2O)cc1,511,-1.0,K-MAP,,
O=C1CCC(c2ccccc2)(C2CCN(Cc3ccc(I)cc3)CC2)C(=O)N1,512,1.209133564,iododexetimide,acetylcholine receptor antagonist,
CC(C)(C)NCC(O)COc1cccc2c1CCCC2=O,513,-1.0,levobunolol-(+/-),adrenergic receptor antagonist,
CNC1CCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1,514,-1.0,balofloxacin,bacterial DNA gyrase inhibitor,
CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)/C2=C\c1ccc(/C=C2\C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1,515,0.717373385,ecamsule-triethanolamine,,
O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,516,0.7758749559999999,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3"
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,517,-1.0,valganciclovir,DNA synthesis inhibitor,
NCC1CC(=O)N(Cc2ccccc2)C1,518,-1.0,nebracetam,acetylcholine receptor agonist,CHRM1
CCCCCCCCCCC(CO)CCCCCCCC,519,-1.0,2-octyldodecan-1-ol,,
COc1ccccc1OCC(O)CNC(C)C,520,-1.0,moprolol,adrenergic receptor antagonist,
C[N+]1(C)C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2,521,-1.0,methylatropine-nitrate,acetylcholine receptor antagonist,CHRM1
CC1COC2(CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)O1,522,-1.0,BTZ043-racemate,DPRE1 inhibitor,
OCC1OC(O)C(F)C(O)C1O,523,-1.0,2-fluoro-2-deoxy-D-galactose,,LCT
CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@@]21C,524,0.9926508159999999,prednisolone-tebutate,anti-inflammatory agent,
CCC[N+]12C3C[C@H](C4C(O)[C@]5(C[C@@H]41)c1ccccc1N(C)[C@@H]35)[C@H](CC)[C@H]2O,525,-1.0,neo-gilurytmal,,
N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1,526,-1.0,PGL5001,JNK inhibitor,"MAPK10, MAPK8, MAPK9"
CCCC[N+]1(C)[C@H]2C[C@H](OC(=O)[C@@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21,527,0.902378494,butylscopolamine-bromide,cholinergic receptor antagonist,
N#C/C(=C1/SCC(c2ccccc2Cl)S1)n1ccnc1,528,1.079979788,lanoconazole,sterol demethylase inhibitor,
C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,529,-1.0,k-strophanthidin,ATPase inhibitor,ATP1A1
CCCC(O)C(CC)CO,530,-1.0,"2-ethyl-1,3-hexanediol",,
Cc1ccc(/C=C2\C(=O)C3(C)CCC2C3(C)C)cc1,531,-1.0,3-(4-methylbenzylidene)camphor,endocrine disruptor,
O=C1/C(=C/c2ccccc2)C[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,532,0.8230638440000001,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1"
CCCCCCCCCCCCCCOS(=O)(=O)O,533,-1.0,sodium-tetradecyl-sulfate,,"PROC, PROS1"
OCC(S)CS,534,-1.0,dimercaprol,chelating agent,
CN1C(=O)CC(C)(c2ccccc2)C1=O,535,-1.0,methsuximide,T-type calcium channel binder,"CACNA1G, CACNA1H, CACNA1I"
O=C(NOCC(O)CO)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,536,0.7600391329999999,PD-318088,MEK inhibitor,MAP2K1
O=C1CCC[C@@H]2[C@@H]3CCC[N+]4([O-])CCC[C@H](CN12)[C@@H]34,537,1.542153816,oxymatrine,,
Fc1cc(F)c2c(c1)[C@H]1C=CC[C@H]1C(c1cccnc1)N2,538,0.9705445220000001,golgicide-a,ARF inhibitor,GBF1
CN1CCc2cc3c(cc2C1O)OCO3,539,-1.0,hydrastinine,haemostatic agent,
CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1,540,0.739901158,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3"
CO[C@H]1CC(O[C@@H]2/C(C)=C/C[C@@H]3C[C@@H](C[C@]4(CC[C@H](C)[C@@H](C5CCCCC5)O4)O3)OC(=O)[C@@H]3C=C(C)/C(=N/O)[C@H]4OC/C(=C\C=C\[C@@H]2C)[C@@]34O)O[C@@H](C)C1O,541,1.118284625,selamectin,nematocide,
C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1,542,1.3889792440000002,ritodrine,adrenergic receptor agonist,ADRB2
CC(C)(CO)[C@@H](O)C(=O)NCCCO,543,-1.0,dexpanthenol,,
O=C(Nc1ccccc1)C12CC1/C(=N\O)c1ccccc1O2,544,-1.0,PHCCC,glutamate receptor agonist,"GRM1, GRM4"
CCCN(C/C=C/I)C1CCc2cccc(O)c2C1,545,0.937646249,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3"
O=C(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(=O)O)C(O3)C(C(O)CO)O4)OC(C(O)CO)C1O2,546,1.2338530840000002,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1"
CC(=O)Oc1c(C)c(C)c2c(c1C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O2,547,-1.0,alpha-tochopheryl-acetate,antioxidant,
CN/C(=N\c1ccc(C2=NNC(=O)CC2C)cc1)NC#N,548,-1.0,siguazodan,phosphodiesterase inhibitor,PDE3A
O=c1[nH]c(=O)n([C@H]2CC(O)[C@@H](CO)O2)cc1/C=C/Br,549,-1.0,brivudine,DNA directed DNA polymerase inhibitor,
CC12C=CCC1C1CCC3CC(=O)CCC3(C)C1CC2,550,-1.0,androstenone,steroid,
NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,551,0.01330602,sangivamycin,DNA inhibitor,
CN1CC2CCCC(C1)C2OC(=O)C(O)(c1ccccc1)C1CCCC1,552,-1.0,levo-phencynonate,acetylcholine receptor antagonist,CHRM1
CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,553,-1.0,diflorasone-diacetate,glucocorticoid receptor agonist,NR3C1
CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O,554,-1.0,NM107,RNA polymerase inhibitor,
CC(=O)NC(C(=O)O)C(C)(C)S[N+][O-],555,-1.0,SNAP,nitric oxide donor,PTPN1
CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O,556,-1.0,hygromycin-b,polypeptide synthesis inhibitor,
O=C1CN2CCN3CCN([C@H](CO)C(O)CO)CCN(CC2)CC(=O)O[Gd](O1)OC(=O)C3,557,-1.0,gadobutrol,radiopaque medium,
CN[C@@H]1C(OC2[C@H](O[C@@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)OC(C)[C@]2(O)CO)OC(CO)C(O)C1O,558,-1.0,dihydrostreptomycin,bacterial 30S ribosomal subunit inhibitor,
O=C1OC(CN2CCOCC2)CN1/N=C/c1ccc([N+](=O)[O-])o1,559,-1.0,furaltadone,bacterial DNA inhibitor,
O=C(CS(=O)Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,560,0.966729477,lafutidine,histamine receptor antagonist,HRH2
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,561,-1.0,pimonidazole,,
COC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1,562,1.31844554,pranidipine,calcium channel blocker,CACNA1C
COc1ccc2c(O[C@H]3CC4C(=O)N(C)CCCC/C=C\[C@@H]5C[C@@]5(C(=O)NS(=O)(=O)C5CC5)NC(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,563,-1.0,simeprevir,HCV inhibitor,"CYP1A2, CYP3A4"
CCC(N)C(O)c1ccc(O)c(O)c1,564,-1.0,ethylnorepinephrine,bronchodilator,
CSC1SCC2C(=O)N(C)C(C(C)C)C(=O)OCC(NC(=O)c3cnc4ccccc4n3)C(=O)NC(C)C(=O)N(C)C1C(=O)N(C)C(C(C)C)C(=O)OCC(NC(=O)c1cnc3ccccc3n1)C(=O)NC(C)C(=O)N2C,565,0.282413176,echinomycin,DNA intercalating agent,
C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,566,1.175964726,cyclosporin-a,calcineurin inhibitor,PPP3CA
C/C(=C(/CCO)SSCC1CCCO1)N(C=O)Cc1cnc(C)nc1N,567,-1.0,fursultiamine,vitamin B,
CSCC1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)O1,568,-1.0,inimur,other antifungal,
CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1,569,-1.0,eprazinone,mucolytic agent,
CO[C@@H]1C(O)[C@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@@H]3C2)OC(C)[C@@H]1O,570,-1.0,peruvoside,cardiac glycoside,
C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,571,-1.0,nalmefene,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1"
OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O,572,-1.0,tagatose,phosphorylase inhibitor,PYGL
CN1CCN(C(=O)C2C(C(=O)O)[C@@H]3CC[C@H]2O3)CC1,573,-1.0,LB-100,protein phosphatase inhibitor,
CO[C@H]1CCC(O[C@H]2CC([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)/C=C(\C)C(=O)[C@H](C)C[C@H](C)C(=O)O)O4)O3)O[C@]3(O[C@@H](C4O[C@@](O)(CO)[C@H](C)C[C@@H]4C)C[C@@H]3C)[C@@H]2C)O[C@@H]1C,574,0.663895176,nanchangmycin,other antibiotic,
NC(Cc1c[nH]c2ccc(O)cc12)C(=O)O,575,-1.0,5-hydroxytryptophan,neurotransmitter,"SLC36A1, SLC36A2"
C[C@H](NC[C@H](O)CP(=O)(O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,576,-1.0,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8"
O=C(O)CCC(CP(=O)(O)O)C(=O)O,577,-1.0,PMPA,glutamate receptor antagonist,FOLH1
C[C@]12CCC3c4ccc(OC(=O)c5ccccc5)cc4CCC3C1CC[C@@H]2O,578,1.298046677,estradiol-benzoate,contraceptive agent,ESR1
CC1=C2[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]3(C)[C@H]4[C@H](CC(N)=O)[C@@](C)(CCC(=O)NC[C@@H](C)OP(=O)(O)O[C@@H]5[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]5O)C5=[N+]4[Co]4(C#N)(N23)[N+]2=C(C=C3[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)C1=[N+]34)C(C)(C)[C@H](CCC(N)=O)C2=C5C,579,-1.0,vitamin-b12,,
CCCCCCCCCCCCCCCC(=O)OC1C(SC)OC(C(NC(=O)C2CC(CCC)CN2C)C(C)Cl)C(O)C1O,580,-1.0,clindamycin-palmitate,bacterial 50S ribosomal subunit inhibitor,
C#CCN1C(C)=C(C(=O)OC)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OCC)=C1C,581,-1.0,MRS1845,calcium channel blocker,
CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O,582,-1.0,editol,,
COc1ccc(CC(=O)NC(N/C(=N/C#N)Nc2cccc3ncccc23)C(C)(C)C)cc1OC,583,-1.0,A740003,purinergic receptor antagonist,P2RX7
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,584,0.7113696509999999,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR"
CCC1/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC2[C@@H](C)C(CC1)OC1(CC[C@@H](C)C(C[C@H](C)O)O1)[C@@H]2C,585,-1.0,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1
CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O,586,-1.0,ardeparin,thrombin inhibitor,"SERPINC1, SERPIND1"
C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,587,-1.0,dexamethasone-sodium-phosphate,glucocorticoid receptor agonist,NR3C1
C=CC[N@@+]12CC[C@]34c5ccccc5N5/C=C6\C7N(/C=C(\C53)[C@@H](C[C@@H]41)/C(=C/CO)C2)c1ccccc1[C@@]71CC[N@@+]2(CC=C)C/C(=C\CO)[C@@H]6C[C@@H]12,588,-1.0,alcuronium,muscle relaxant,"CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7"
O=C(O)/C=C1\CCCc2ccccc2C1O,589,-1.0,NCS-382,GABA receptor antagonist,"GABBR1, GABBR2, SLC52A2"
O=C1O[C@H]([C@@H](O)CO)C(O)C1=O,590,-1.0,ascorbic-acid,antioxidant,"ALKBH2, ALKBH3, BBOX1, DBH, EGLN1, EGLN2, EGLN3, KDM5D, LCT, OGFOD1, OGFOD2, P3H1, P3H2, P3H3, P4HA1, P4HTM, PAM, PHYH, PLOD1, PLOD2, PLOD3, SLC23A1, SLC23A2, TMLHE"
CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,591,1.3160879079999999,clopamide,sodium/chloride cotransporter inhibitor,
CCN(CC)CCCCC(NC(=O)c1ccc([N+](=O)[O-])cc1)c1ccccc1,592,-1.0,nibentan,potassium channel blocker,
C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O,593,-1.0,L-(+)-Rhamnose-Monohydrate,,
C=C1CCC2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,594,-1.0,andrographolide,tumor necrosis factor production inhibitor,NFKB1
CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC,595,-1.0,moguisteine,ATP-sensitive potassium channel inhibitor,
CCOc1ccc(NC(=O)CC(C)O)cc1,596,-1.0,bucetin,analgesic agent,
C[N+](C)(C)CC(O)CC(=O)O,597,-1.0,carnitine-(D/L),,
C/C(=C\C(N)C(=O)O)CP(=O)(O)O,598,-1.0,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D"
O=C(CS(=O)C(c1ccccc1)c1ccccc1)NO,599,-1.0,adrafinil,adrenergic receptor agonist,
CCC(C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](OC3C[C@H](OC)C(O[C@H]4C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,600,1.494766281,eprinomectin,benzodiazepine receptor agonist,
CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1,601,1.133147014,camylofine-chlorhydrate,,
COc1ccc(CC2NCCc3cc(OC)c(OC)cc32)cc1OC,602,-1.0,tetrahydropapaverine,,
O=C(O)C1=CC(O)C(O)[C@H](O)C1,603,-1.0,shikimic-acid,,
CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,604,0.9066571240000001,N-acetylmannosamine,,CHIT1
O=c1ncnc2n([C@@H]3O[C@H](CO)[C@H](O)C3O)[nH]cc1-2,605,-1.0,allopurinol-riboside,anti-leishmanial agent,
O=C(O)C(O)Cc1ccc(O)c(O)c1,606,-1.0,sodium-danshensu,,
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,607,-1.0,telithromycin,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7"
COC(=O)CCSCc1ccc(-c2onc(C)c2NC(=O)OC(C)c2ccccc2Cl)cc1,608,-1.0,ki16198,lipoprotein antagonist,LPA
C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@]36[C@@H](OC(=O)[C@@H]6O)O[C@@]4(C(=O)O5)[C@]21O,609,1.118945969,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB"
CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,610,-1.0,methyclothiazide,chloride reabsorption inhibitor,"CA1, CA2, CA4, SLC12A1, SLC12A3"
CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,611,-1.0,talarozole,cytochrome P450 inhibitor,CYP26A1
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC,612,1.171758419,colfosceril-palmitate,pulmonary surfactant,
C[C@@]12CCC3[C@]4(C)CCC[C@@](C)(C(=O)O)[C@H]4CC[C@]3(CC1=O)C2,613,-1.0,isosteviol,,
CCCCCC(O)CCCC(=O)O,614,-1.0,M-14157,ATP-sensitive potassium channel antagonist,KCNQ1
OCC(O)[C@H]1O[C@@H]2O[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@H]1O,615,-1.0,chloralose,,
CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C,616,-1.0,metipranolol,adrenergic receptor antagonist,"ADRB1, ADRB2"
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,617,1.2905364590000001,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C"
C=CCn1c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2nc(N)[nH]c(=O)c21,618,-1.0,RWJ-21757,toll-like receptor agonist,TLR7
O=C(O)/C=C/c1ccc(-c2ccc(O)c(C34CC5CC(CC(C5)C3)C4)c2)cc1,619,-1.0,adarotene,retinoid receptor agonist,"RARB, RARG"
Oc1cc(O)cc(O)c1,620,-1.0,phloroglucin,,
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N,621,-1.0,peramivir,neuraminidase inhibitor,
Nc1c2ccccc2nc2ccccc12,622,0.838546232,9-aminoacridine,,
NC(N)=Nc1nc(CSCC/C(N)=N\S(N)(=O)=O)cs1,623,1.113053108,famotidine,histamine receptor antagonist,HRH2
N[C@H](Cc1ccccc1)C(=O)O,624,-1.0,D-Phenylalanine,enkephalinase inhibitor,"CCBL1, CRH, HCAR3"
N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)O,625,-1.0,IMREG-1,,
O=C(O)c1ccccn1,626,1.227484385,picolinic-acid,chelating agent,
CC(C)=CCOc1ccc(/C=C/C(=O)c2ccc(OCC=C(C)C)cc2OCC(=O)O)cc1,627,-1.0,sofalcone,mucus protecting agent,CBR1
CC(=O)OC[C@H]1O[C@H](O[C@]2(COC(C)=O)O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O,628,-1.0,sucrose-octaacetate,,
O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1,629,-1.0,uric-acid,,PYGL
CC(C)(C)NS(=O)(=O)c1cncc(-c2cc(F)c3nc(N)nn3c2)c1,630,-1.0,CZC24832,PI3K inhibitor,PIK3CG
O=C1c2c(O)cc(O)cc2O[C@H](c2cc(O)c(O)c(O)c2)[C@H]1O,631,0.9860938229999999,dihydromyricetin,,
Oc1ccc(Cl)c2c1CCC2,632,1.027263303,chlorindanol,,
NC(=S)N/N=C/c1ncccc1N,633,0.800524557,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2"
CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,634,0.703289218,TAK-901,Aurora kinase inhibitor,AURKB
C[N+](C)(C)CC#CCN1CCCC1=O,635,-1.0,oxotremorine-m,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4"
CC(C)(C)c1ccc(/C=C/C(=O)Nc2ccc3c(c2)OCCO3)cc1,636,-1.0,AMG-9810,TRPV antagonist,TRPV1
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,637,0.7284022309999999,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9"
CCOC(=O)c1ccc(O)cc1,638,-1.0,ethyl-paraben,,
CCOc1cc(NC(C)=O)ccc1C(=O)OC,639,-1.0,ethopabate,antiprotozoal agent,
Nc1ccc(S(N)(=O)=O)cc1,640,0.951850325,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4"
CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@H](c4ccoc4)OC(=O)[C@H]4O[C@]43[C@]12C,641,-1.0,gedunin,HSP inhibitor,HSP90AA1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,642,-1.0,cefuroxime,bacterial cell wall synthesis inhibitor,
O=C(O)c1cc2cccc([N+](=O)[O-])c2[nH]1,643,-1.0,CRT0044876,,
CCCN1CCC[C@H](c2cccc(O)c2)C1,644,-1.0,preclamol,dopamine receptor agonist,DRD2
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1,645,-1.0,SU-11274,"hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor",MET
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CC[C@@H](O)C(C)(C)O,646,-1.0,secalciferol,vitamin D receptor agonist,VDR
O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1,647,-1.0,GSK3787,PPAR receptor antagonist,PPARD
O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1,648,1.473914056,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B"
Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(-c5ccc(N6CCN(C)CC6)cc5)nc34)CC2)no1,649,0.7537972390000001,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC"
Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F,650,0.759880601,XL388,mTOR inhibitor,MTOR
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,651,0.594420951,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8"
COc1c(O)cc2c(c1O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1OC2=O,652,-1.0,bergenin,interleukin inhibitor,"IL1B, TNF"
N#Cc1ccncn1,653,1.433484781,4-pyrimidinecarbonitrile,,
CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(=NCCCCCCCC)cc2)cc1,654,0.826168682,octenidine,membrane integrity inhibitor,
C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@@H]1C(=O)N(C)c2ccccc2-c2ccccc21,655,0.902447351,YO-01027,gamma secretase inhibitor,
C/C(=C\C(=O)Nc1ccccc1C(=O)O)c1ccc2ccccc2c1,656,0.8960940940000001,BIBR-1532,telomerase inhibitor,TERT
Cc1cc(O)cc2c1O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,657,-1.0,D-delta-Tocopherol,,
O=C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc21,658,-1.0,aloe-emodin,anticancer agent,CASP8
O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N/O,659,1.479179576,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B"
CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO,660,-1.0,phytosphingosine,,
C[C@H](NC(=O)/C(C#N)=C/c1cccc(Br)n1)c1ccccc1,661,0.74147057,WP1066,STAT inhibitor,STAT3
FCOC(C(F)(F)F)C(F)(F)F,662,0.9127721540000001,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1"
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,663,-1.0,dexlansoprazole,ATPase inhibitor,"ATP4A, ATP4B"
CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,664,-1.0,nonivamide,TRPV agonist,TRPV1
CCOC(=S)SSC(=S)OCC,665,-1.0,dixanthogen,,
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,666,1.14892062,posaconazole,sterol demethylase inhibitor,CYP3A4
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,667,-1.0,rilpivirine,non-nucleoside reverse transcriptase inhibitor,"NR1I2, SCN10A"
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,668,-1.0,fludrocortisone-acetate,,"AR, NR3C1, NR3C2"
CCCCCCCC/C=C\CCCCCCCC(N)=O,669,-1.0,oleamide,cannabinoid receptor agonist,"HTR7, PLA2G2A"
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,670,0.8955730049999999,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5
CN[C@@H]1[C@H](OC2[C@H](O[C@@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,671,-1.0,streptomycin,bacterial 30S ribosomal subunit inhibitor,
COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,672,0.772921596,frentizole,immunosuppressant,
O=C(Nc1cc(Cl)cc(Cl)c1O)c1c(O)c(Cl)cc(Cl)c1Cl,673,-1.0,oxyclozanide,,
C/C(=C(/CCOP(=O)(O)O)SC(=O)c1ccccc1)N(C=O)Cc1cnc(C)nc1N,674,1.459516181,benfotiamine,antioxidant,AGER
CCC(=O)c1ccc(O)cc1,675,-1.0,paroxypropione,gonadotropin inhibitor,
CCOc1ccccc1N/N=C1/C(=O)N(c2nc(-c3ccccc3)cs2)N=C1C,676,0.885897791,BAM7,BAX activator,BAX
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,677,0.9411663709999999,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH"
COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,678,0.429308416,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG"
CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]2O)N(C)C1,679,-1.0,lincomycin,bacterial 30S ribosomal subunit inhibitor,
CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O,680,-1.0,danoprevir,HCV inhibitor,
CC(C)(O)[C@H]1CC[C@@](C)([C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]5C(C)(C)[C@@H](O[C@@H]6OC[C@@H](O)[C@H](O)[C@H]6O)CC[C@@]56C[C@@]46CC[C@]23C)O1,681,-1.0,astragaloside-a,antiinflammatory agent,
Oc1ccc(-c2nc3cc(O)cc(Br)c3o2)cc1,682,-1.0,WAY-200070,estrogen receptor agonist,"ERBB2, ERBB3, ERBB4, ESR2"
CNC(=O)Oc1ccccc1OC(C)C,683,-1.0,propoxur,,
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(O)(C(F)(F)F)C(F)(F)F)C[C@@H](O)C[C@@H]1O,684,-1.0,falecalcitriol,vitamin D receptor agonist,VDR
CCN1CCCC1=O,685,-1.0,1-ethyl-2-pyrrolidone,transdermal absorption-enhancing compound,
CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O,686,0.871305408,gambogic-acid,caspase activator,BCL2
O=C(CCCl)NCCc1ccccc1,687,1.002904475,fenaclon,,
CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,688,0.850028869,pelitinib,EGFR inhibitor,EGFR
CCOc1ccc(S(=O)(=O)O)c2cccnc12,689,-1.0,actinoquinol,,
COC(=O)/C=C/c1cccc(N(Cc2ccc(-c3ccc(N(C)C)cc3)cc2)C(=O)C2CCCCC2)c1,690,-1.0,fexaramine,FXR agonist,NR1H4
Cc1ccc(-n2sc(=O)n(Cc3ccc(F)cc3)c2=O)cc1,691,0.949049875,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8"
CC(C)C(=O)c1ccc(O)c(O)c1,692,-1.0,U-0521,catechol O methyltransferase inhibitor,COMT
CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(S(C)(=O)=O)cc1,693,-1.0,firocoxib,cyclooxygenase inhibitor,PTGS2
NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,694,-1.0,nepicastat,dopamine beta hydroxylase inhibitor,DBH
NS(=O)(=O)c1ccc(C(=O)O)cc1,695,-1.0,carzenide,,"CA1, CA12, CA14, CA2, CA6, CA9"
CCCCCCCCO,696,-1.0,1-octanol,,"GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1"
CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1,697,0.752513002,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC"
O=C(Nc1c(-c2cccs2)nc2ccccn12)c1ccc(Cl)cc1,698,-1.0,DS2-(806622),,
Cl/C(=C\n1cncn1)c1ccc(Cl)cc1Cl,699,-1.0,loreclezole,benzodiazepine receptor agonist,"GABRB2, GABRB3"
C=C[C@@](C)(/C=C/c1ccc(O)cc1)CCC=C(C)C,700,-1.0,bakuchiol,DNA polymerase inhibitor,HIF1A
O=C(O)/C=C/c1ccc(O)c(O)c1,701,1.2671148140000001,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF"
C[n+]1ccc(C(=O)NCc2ccccc2)cc1,702,-1.0,enisamium-iodide,,
N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,703,-1.0,besifloxacin,bacterial DNA gyrase inhibitor,
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,704,0.9271709309999999,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1"
O=C[C@H](O)[C@@H](O)[C@H](O)CO,705,-1.0,xylose,,
N[C@@H]1CN(c2c(F)cc3c(=O)c(C(=O)O)cn([C@@H]4C[C@@H]4F)c3c2Cl)CC12CC2,706,-1.0,sitafloxacin,bacterial DNA gyrase inhibitor,
O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1,707,-1.0,OAC1,Oct activator,
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,708,-1.0,silodosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D"
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,709,0.966167587,latanoprost,prostanoid receptor agonist,PTGFR
CN1CCN(c2nc3ccccc3nc2Cl)CC1,710,-1.0,VUF10166,serotonin receptor antagonist,"HTR3A, HTR3B"
NC(=O)CCCCn1ccc(/N=C(\N)NCC(F)(F)F)n1,711,1.3388075590000001,ICI-162846,histamine receptor antagonist,HRH2
CC(=O)Nc1ccccc1,712,-1.0,acetanilide,hydrogen peroxide decomposition inhibitor,
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,713,-1.0,gadoterate-meglumine,radiopaque medium,
Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1,714,-1.0,ceftibuten,bacterial cell wall synthesis inhibitor,
N=C(N)N=Nc1ccc(NNC(=N)S)cc1,715,1.205882336,ambazone,DNA damage inducer,
N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O,716,-1.0,NOV-002,,"GSR, GSTM2"
CC(=O)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C,717,1.0260609729999999,teprenone,mucus protecting agent,
C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O,718,-1.0,dipeptamin,,
c1cc2c(cc1[C@H]1OC[C@@H]3[C@@H](c4ccc5c(c4)OCO5)OC[C@H]13)OCO2,719,-1.0,sesamin,NFkB pathway inhibitor,
C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@]1(O)CC[C@]2(O)c1ccoc1,720,-1.0,rostafuroxine,ATPase inhibitor,ATP1A1
Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,721,-1.0,triprolidine,histamine receptor antagonist,HRH1
O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1,722,-1.0,furazolidone,bacterial DNA inhibitor,
Cc1cc(=O)[nH]c(=S)[nH]1,723,-1.0,methylthiouracil,,
C[N+](C)(C)CC(=O)O,724,-1.0,betaine,nitric oxide donor,
O=P(O)(NCCCl)NCCCl,725,-1.0,palifosfamide,DNA alkylating agent,
O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1,726,0.8130550809999999,LY2608204,glucokinase activator,GCK
N#C/C(=C(/N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F,727,0.636937641,MEK1-2-inhibitor,MEK inhibitor,MAP2K2
C/C(=C(/CCOC(=O)C(C)C)SS/C(CCOC(=O)C(C)C)=C(\C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N,728,-1.0,sulbutiamine,acetylcholine receptor antagonist,
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(NCCc4ccc(CCC(=O)O)cc4)nc32)[C@@H](O)[C@@H]1O,729,-1.0,CGS-21680,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3"
C1CCC(N/C(=N/C23CC4CC(CC(C4)C2)C3)N2CCOCC2)CC1,730,-1.0,PNU-37883,ATP-sensitive potassium channel antagonist,
CN(CCCl)CCCl,731,0.921448335,mechlorethamine,DNA inhibitor,
O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,732,1.2834872640000001,uridine,dopamine receptor agonist,"LSM6, TYMP"
CC(C)[C@H](C(=O)Nc1ccc(C(=O)NO)cc1)c1ccccc1,733,0.864111385,AR-42,HDAC inhibitor,HDAC1
O=c1[nH]c(=O)c2ccccc2o1,734,-1.0,carsalam,analgesic agent,
COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC,735,1.3411208609999998,KY02111,Wnt pathway inhibitor,DKK1
CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,736,1.200388436,ebastine,histamine receptor antagonist,"CYP3A4, HRH1"
CCCCCCCCCCCCCC(=O)OC(C)C,737,0.8526959940000001,isopropyl-myristate,,
Nc1nccs1,738,-1.0,aminothiazole,cyclin D inhibitor,NOS2
NC(=O)NS(=O)(=O)c1ccc(N)cc1,739,-1.0,sulfacarbamide,,
CN1CC(=O)NC1=N,740,-1.0,creatinine,,
C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)c(C(=O)CCc4ccc(O)cc4)c(O)c3)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,741,-1.0,naringin-dihydrochalcone,cytochrome P450 inhibitor,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,742,0.9499839784999999,everolimus,mTOR inhibitor,MTOR
CC(=O)N[C@@H](CCC(N)=O)C(=O)O,743,-1.0,aceglutamide,,
C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2,744,-1.0,IEM1460,glutamate receptor antagonist,GRIA2
CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,745,-1.0,isopropamide-iodide,acetylcholine receptor antagonist,"CHRM3, CHRM4"
COc1ccc(/C=C2\CCCN=C2c2cccnc2)c(OC)c1,746,-1.0,GTS21,cholinergic receptor agonist,CHRNA7
Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,747,1.093224892,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,748,-1.0,NECA,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, HSP90B1"
COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1,749,-1.0,avobenzone,UV blocker,TYR
CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21,750,-1.0,meisoindigo,STAT inhibitor,STAT3
CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,751,0.7586317290000001,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2"
CCc1cncnc1N1CCN(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)CC1,752,-1.0,PF-4708671,ribosomal protein inhibitor,RPS6KB1
CCN(CC)CCNC(=O)c1ccc(I)cc1,753,-1.0,I-BZA,,
FC(F)(F)COCC(F)(F)F,754,-1.0,flurothyl,,
Cc1ccc(S(=O)(=O)/C=C/C#N)cc1,755,0.989295198,BAY-11-7082,NFkB pathway inhibitor,RELA
COc1ccc(NS(=O)(=O)c2ccc(N=Nc3ccc(O)c(C(=O)O)c3)cc2)nn1,756,-1.0,salazodine,,
CN/C(=N\C#N)NCCSCc1csc(N=C(N)N)n1,757,0.9495493620000001,tiotidine,histamine receptor antagonist,HRH2
CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@]12C,758,-1.0,hemomex-s,,PPARG
CCOC(=O)c1c[nH]cn1,759,-1.0,C-751,,
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,760,0.7241540625,obatoclax,BCL inhibitor,BCL2
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,761,-1.0,ursodiol,"nuclear factor erythroid derived, like (NRF2) activator",NR1H4
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,762,1.4760494569999998,cefdinir,bacterial cell wall synthesis inhibitor,MPO
COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2,763,0.28724768300000003,maytansinol-isobutyrate,,
c1cc[n+]2c(c1)S[Zn]1(O2)O[n+]2ccccc2S1,764,0.689588042,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5"
COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3,765,-1.0,metocurine,acetylcholine receptor antagonist,"CHRM2, CHRNA2"
Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1,766,0.975928425,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP
FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F,767,-1.0,perfluamine,,
c1ccc2[nH]c(-c3nc4ccccc4[nH]3)nc2c1,768,1.426827681,pibenzimol,DNA inhibitor,
O=[N+]([O-])c1ccc2c(c1)S(=O)(=O)C=C2,769,0.860667223,stattic,,
C[C@@H](Oc1ccc2[nH]nc(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,770,0.700836968,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR"
C[C@H](NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,771,-1.0,tyrphostin-AG-835,protein tyrosine kinase inhibitor,EGFR
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,772,-1.0,abacavir,nucleoside reverse transcriptase inhibitor,
O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,773,-1.0,butein,"EGFR inhibitor, src inhibitor",ACE
CC(C)(S)[C@@H](N)C(=O)O,774,0.7510859679999999,penicillamine-(D),chelating agent,
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,775,0.8741308864999999,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"
CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1,776,-1.0,JNJ-7777120,histamine receptor antagonist,HRH4
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,777,0.8803351620000001,tranilast,angiogenesis inhibitor,"HPGDS, HRH1"
O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(Cl)c1,778,-1.0,cloprostenol-(+/-),prostaglandin receptor agonist,"PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R"
O=C1Nc2ccccc2/C1=C1/Nc2ccccc2C1=O,779,1.126289982,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A"
CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1,780,-1.0,oxelaidin,antitussive,
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)O,781,-1.0,gamma-linolenic-acid,"cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2"
CCOc1ccc2nc(S(N)(=O)=O)sc2c1,782,-1.0,ethoxzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9"
CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O,783,-1.0,uridine-triacetate,,
NCCCNCCCCNCCCN,784,0.941705639,spermine,,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5"
Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,785,0.868410096,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC"
COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,786,1.189606567,mexeneone,,
CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1,787,-1.0,benzoquinonium-dibromide,cholinergic receptor antagonist,CHRNA1
N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(\N)Sc1ccccc1N,788,1.350176133,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1"
Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O,789,-1.0,clevudine,DNA polymerase inhibitor,
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,790,0.8754366020000001,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3"
FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,791,0.724315747,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2"
O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O,792,-1.0,indirubin-3-monoxime,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B"
CCCC(C)(COC(N)=O)COC(N)=O,793,-1.0,meprobamate,,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ"
CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(=O)O,794,0.897329704,FR-139317,endothelin receptor antagonist,EDNRA
CN(CC(=O)O)C(=N)N,795,1.028893603,creatine,,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8"
O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12,796,-1.0,compound-401,DNA dependent protein kinase inhibitor,"MTOR, PRKDC"
CCn1cnc(C(=O)NC)c1C(=O)NC,797,-1.0,ethimizol,,
Cc1ccccc1CN1CC2=C(CCN(Cc3ccccc3)C2=O)N2CCN=C12,798,-1.0,TIC10,"AKT inhibitor, TRAIL modulator","AKT1, MAPK1"
CCCC[C@@H](CC)COC(=O)/C=C/c1ccc(OC)cc1,799,-1.0,octinoxate,,
C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@@H]1C(=O)N(C)c2ccccc2-c2ccccc21,800,-1.0,LY411575,gamma secretase inhibitor,
CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O,801,-1.0,dihomo-gamma-linolenic-acid,prostanoid receptor agonist,"PTGS1, PTGS2"
CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(N)=O)ccc32)c2ccccc2)c1,802,0.8861350640000001,BIX-02188,MEK inhibitor,MAP2K5
O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,803,-1.0,rosmarinic-acid,GABA transaminase inhibitor,"MCL1, TYR"
O=C(O)c1ccc[n+]([O-])c1,804,-1.0,oxiniacic-acid,,
O=C(Nc1ccc(C(=O)O)c(O)c1)c1ccccc1,805,-1.0,benzoylpas,,
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,806,0.816773946,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG"
O=C(CN1C(=O)c2ccccc2S1(=O)=O)Nc1ccc(O)cc1,807,-1.0,SCP-1,analgesic agent,
CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,808,-1.0,pramiracetam,acetylcholine receptor agonist,
C[C@H](N)Cc1ccccc1,809,-1.0,dextroamphetamine,monoamine oxidase inhibitor,"ADRA1A, ADRA1B, SLC18A2, SLC6A2, SLC6A3, TAAR1"
Oc1ccc2ccccc2c1,810,0.95179482,beta-naphthol,,
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,811,0.5752677165,selinexor,exportin antagonist,XPO1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(C)CS[C@H]12)c1csc(N)n1,812,-1.0,cefetamet-pivoxil,bacterial cell wall synthesis inhibitor,
Nc1ncnc(Nc2ccc(Cl)cc2)n1,813,-1.0,chlorazanil,,
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,814,0.975307115,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B"
CC(=O)NO,815,-1.0,acetohydroxamic-acid,urease inhibitor,MMP12
Clc1ccc(CCCOCCCN2CCCCC2)cc1,816,1.241097688,BF2.649,histamine receptor antagonist,HRH3
O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,817,0.81385999,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3"
O=C(O)c1ccccc1-c1c2cc(Br)c(=O)cc-2oc2c([Hg]O)c(O)c(Br)cc12,818,-1.0,merbromin,antiseptic,
COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,819,0.98691801,AMG458,MET inhibitor,MET
N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1,820,-1.0,AZD1208,Pim kinase inhibitor,"PIM1, PIM2, PIM3"
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,821,-1.0,fluorescein,,SLC22A6
CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(=O)O,822,1.271966423,loxistatin-acid,cysteine peptidase inhibitor,CTSB
CCN(CC)CCO[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1,823,0.906507755,U-18666A,oxidosqualene cyclase inhibitor,
CCOC(=O)c1ccc(OCCC2CCN(c3ccc(C)nn3)CC2)cc1,824,-1.0,pirodavir,,
Cc1ccccc1/N=N/c1ccc(NC(=O)c2ccnn2C)c(C)c1,825,-1.0,CH223191,aryl hydrocarbon receptor antagonist,AHR
Nc1nonc1/C(=N\c1ccc(F)c(Cl)c1)NO,826,-1.0,IDO5L,"indoleamine 2,3-dioxygenase inhibitor",IDO1
CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,827,0.878162608,DVD-111,,
CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N/C(=N/C2CCCCC2)NC2CCCCC2)cc1,828,-1.0,WIN-64338,bradykinin receptor antagonist,BDKRB2
Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1,829,-1.0,ZCL-278,CDC inhibitor,CDC42
CC(=O)N[C@@H]1[C@@H](NC(=N)N)C=C(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO,830,-1.0,zanamivir,neuraminidase inhibitor,NEU2
CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,831,0.9671495309999999,benzyldimethylhexadecylammonium,cationic surfactant,
COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,832,-1.0,volinanserin,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C, KCNH2"
C=C1C(=O)[C@]23[C@H](O)[C@H]1CC[C@@H]2[C@@]12CO[C@]3(O)C[C@@H]1C(C)(C)CC[C@@H]2O,833,0.9094241740000001,oridonin,BCL inhibitor,BCL2
Cc1noc(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,834,1.4989040480000002,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,835,-1.0,travoprost,prostanoid receptor agonist,PTGFR
Nc1ccc([As](=O)(O)O)cc1,836,-1.0,arsanilic-acid,,LYZ
CCOc1cncc(/C=C/CCNC)c1,837,-1.0,TC2559,acetylcholine receptor agonist,CHRNA4
COc1cc(C=O)ccc1O,838,-1.0,vanillin,,"ABAT, ALDH5A1"
O=C(NN1C(=O)[C@H]2[C@H]3C=C[C@H]([C@@H]4C[C@H]34)[C@H]2C1=O)c1ccc(C(F)(F)F)cc1,839,-1.0,tecovirimat,orthopoxvirus egress inhibitor,
CCN(CC)S(=O)(=O)c1ccc(C(=O)O)cc1,840,-1.0,etebenecid,uricosuric blocker,
COc1cc(/C=C/C(N)=O)cc(OC)c1OC,841,-1.0,cintriamide,,
Cc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4c3O)c(C)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2c1O,842,-1.0,evans-blue,glutamate receptor negative allosteric modulator,"GRIA1, PTPN1"
CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C,843,1.174027481,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,844,-1.0,bucillamine,immunosuppressant,
CCOc1ccc2nc3cc(N)ccc3c(N)c2c1,845,0.94556248,ethacridine-lactate-monohydrate,DNA intercalating agent,
CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,846,-1.0,tricaprylin,,
Cc1nc(Cn2cnc3c2c(=O)n(C)c(=O)n3C)no1,847,-1.0,CH-170,,
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC4CN(CCF)C4)cc3OC)ncc2C(F)(F)F)c1,848,0.925320444,CNX-2006,EGFR inhibitor,EGFR
CCCC[C@H](C)C[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)O,849,-1.0,limaprost-alfadex,prostanoid receptor agonist,PTGER1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,850,1.229406884,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET"
O=C(c1cccc(Cl)c1F)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,851,0.6782296720000001,MK-8745,Aurora kinase inhibitor,AURKA
Cc1nccnc1N1CCCCC1,852,-1.0,modaline,,
CC[C@H](CO)Nc1nc(Nc2cccc(-c3ccccn3)c2)c2ncn(C(C)C)c2n1,853,-1.0,DRF053-(R),CDK inhibitor,CSNK1A1
CO[C@H]1CC[C@@H](C(=O)c2ccc3nc4c(cc3c2)CCCO4)CC1,854,1.4997378209999999,JNJ-16259685,glutamate receptor antagonist,GRM1
Cc1nc(C)c(C)nc1C,855,-1.0,chuanxiongzine,,
CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,856,-1.0,tapentadol,opioid receptor agonist,"HTR3A, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4"
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O,857,1.21277196,josamycin,bacterial 50S ribosomal subunit inhibitor,
CC1(C)CCC(C)(C)c2cc(C3(c4ccc(C(=O)O)cc4)OCCO3)ccc21,858,-1.0,BMS-649,retinoid receptor agonist,RXRA
Nc1ncnc2[nH]cnc12,859,-1.0,adenine,protein synthesis stimulant,"ACACB, ACP1, APRT, MTAP, PECR, SRPK2"
C=CCc1ccc(O)c(-c2cc(CC=C)ccc2O)c1,860,-1.0,magnolol,PPAR receptor agonist,"GABRA1, PPARG"
CCCCC/C=C\C=C\CCCCCCCCC(=O)O,861,-1.0,"trans-10,cis-12-Conjugated-linoleic-acid",,
Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(S(C)(=O)=O)cc1,862,0.697615955,NMS-873,ATPase inhibitor,VCP
O=C(CCCS)NC1CCN(C(=O)COc2ccc(Cl)cc2Cl)CC1,863,0.973253355,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,
COc1cc(C(=S)N2CCOCC2)ccc1O,864,-1.0,vanitiolide,,
CN(C)c1ccc(/C=C2\CCCN=C2c2cccnc2)cc1,865,-1.0,DMAB-anabaseine,adrenergic receptor agonist,CHRNA7
COC(=O)c1cc(OC)c2c(c1-c1c(C(=O)OC)cc(OC)c3c1OCO3)OCO2,866,-1.0,bifendate,,
CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)/C=C/C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,867,1.279352797,tilmicosin,bacterial 50S ribosomal subunit inhibitor,
O=[N+]([O-])c1ncc[nH]1,868,-1.0,azomycin-(2-nitroimidazole),protein synthesis inhibitor,
C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CC[C@@H]12,869,1.220026917,costunolide,telomerase inhibitor,
COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O,870,-1.0,diosmetin,aryl hydrocarbon receptor agonist,CYP1B1
O=c1c2ccccc2oc2ccccc12,871,-1.0,xanthone,antimalarial agent,
N[C@@H](Cc1cc(CP(=O)(O)O)cc(-c2ccccc2Cl)c1)C(=O)O,872,-1.0,SDZ-220-581,glutamate receptor antagonist,GRIN1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,873,0.8336410740000001,calcitriol,vitamin D receptor agonist,VDR
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,874,-1.0,piperaquine-phosphate,antimalarial agent,
Cc1cccc(C)c1NC(=O)c1cc(S(N)(=O)=O)c(Cl)cc1O,875,-1.0,xipamide,carbonic anhydrase inhibitor,SLC12A3
O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12,876,-1.0,H-89,PKA inhibitor,"GSG2, PKIA, PRKACA"
CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)N(C)C1,877,0.90745482,clindamycin-phosphate,protein synthesis inhibitor,
CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](NC)CC[C@@]45C[C@@]35CC[C@]12C,878,-1.0,cyclovirobuxin-d,calcium channel modulator,
Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,879,-1.0,flucloxacillin,bacterial cell wall synthesis inhibitor,
C[C@H](N)Cn1ccc2cc(F)c(Cl)cc21,880,-1.0,Ro-60-0175,,"HTR2A, HTR2B, HTR2C"
COc1ccc(C2(O)CCC(N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1,881,-1.0,INCB-003284,CC chemokine receptor antagonist,
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@H]21,882,-1.0,parthenolide-(alternate-stereo),NFkB pathway inhibitor,"IKBKB, RELA"
CC(=O)NCC(=O)N[C@H](CCC(=O)O)C(=O)O,883,-1.0,N-acetylglycyl-D-glutamic-acid,glutamate receptor agonist,
CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C,884,-1.0,20-hydroxyecdysone,ecdysone receptor modulator,
CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,885,0.7877900390000001,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG"
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,886,1.223026666,AP1903,,
CCOC(=O)c1c(C)n(C)c2ccc(O)cc12,887,-1.0,mecarbinate,,
[N-]=[N+]=N[C@]1(CO)O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,888,-1.0,R-1479,HCV inhibitor,
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/C=C/C(O)(CC)CC)C[C@@H](O)C[C@@H]1O,889,-1.0,seocalcitol,vitamin D receptor agonist,VDR
OCc1ccccn1,890,-1.0,piconol,,
COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1,891,0.939858192,A-803467,sodium channel blocker,SCN10A
C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@@]32C)O[C@]12CC[C@@H](C)CO2,892,-1.0,diosgenin,steroid,
OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1,893,-1.0,zuclopenthixol,dopamine receptor antagonist,"ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A"
CN(C)Cc1ccc(S(=O)(=O)n2ccc(/C=C/C(=O)NO)c2)cc1,894,0.9440495000000001,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8"
O=C(Nc1ccccc1)Nc1ccc(-c2ccc(C(=O)[C@@H]3CCC[C@@H]3C(=O)O)cc2)cc1,895,-1.0,A922500,diacylglycerol O acyltransferase inhibitor,DGAT1
CCc1nc(C)ccc1O,896,-1.0,emoxipin,,
O=C(O)CCC/C=C\C[C@@H]1CO[C@H](C(F)(F)F)O[C@@H]1c1ccccc1O,897,-1.0,"ICI-185,282",thromboxane receptor antagonist,
Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,898,-1.0,flunarizine,calcium channel blocker,"CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1"
COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,899,-1.0,SKLB1002,VEGFR inhibitor,KDR
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,900,0.8935770865,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4"
N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,901,-1.0,glucosamine,glycosylated protein precursor,"IFNG, IL1B, MMP9, NFKB2, TNF"
CCN(CC)CCOc1ccc(/C(=C(\Cl)c2ccccc2)c2ccccc2)cc1,902,0.824565517,clomifene,estrogen receptor antagonist,ESR1
N[C@@H](COP(=O)(O)O)C(=O)O,903,-1.0,dexfosfoserine,membrane integrity inhibitor,"CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2"
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,904,-1.0,fenofibric-acid,cytochrome P450 inhibitor,"CLCN1, PPARA"
CC(=N)NCc1cccc(CN)c1,905,-1.0,1400W,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3"
COc1ccc(/C=C/C(=O)CC(=O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,906,-1.0,ASC-J9,androgen receptor enhancer,AR
C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,907,-1.0,dutasteride,5 alpha reductase inhibitor,"SRD5A1, SRD5A2"
CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,908,0.9001005679999999,domiphen,,
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,909,-1.0,rifabutin,protein synthesis inhibitor,"HSP90AA1, HSP90B1"
CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,910,-1.0,eletriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7"
Cc1ccc(/C=N/NC(=O)c2ccccc2Oc2ccccc2)o1,911,-1.0,PNU-74654,beta-catenin inhibitor,"CTNNB1, TCF4"
CCCCCCCCCCCCCCCC(=O)OC(C)C,912,-1.0,isopropyl-palmitate,cosmetic moisturizer,
CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(c23)C1=O,913,0.8773922140000001,UNBS-5162,CC chemokine receptor antagonist,
Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc32)nc2cccc(C)c2c1=O,914,-1.0,PIK-293,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG"
COC(=O)/C=C/C(=O)OC,915,-1.0,dimethyl-fumarate,"nuclear factor erythroid derived, like (NRF2) activator",KEAP1
O=C(O)c1nc(=O)[nH]c(=O)[nH]1,916,1.267391334,oxonic-acid,uricase inhibitor,
CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1,917,-1.0,olvanil,TRPV agonist,"CNR1, GPR119, TRPV1"
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,918,1.1109536845,icotinib,EGFR inhibitor,EGFR
N#Cc1c(Oc2ccc(F)c(NC(=O)Cc3cccc(C(F)(F)F)c3)c2)ccc2nc(NC(=O)C3CC3)sc12,919,0.789234453,TAK-632,RAF inhibitor,BRAF
CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,920,0.8998831829999999,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS"
CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc21,921,-1.0,EHop-016,Ras GTPase inhibitor,"RAC1, RAC3"
CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(=O)O)C(=O)O,922,0.822924935,D-7193,,
O=C(O)c1cc(=O)[nH]c(=O)[nH]1,923,1.135799684,orotic-acid,,DHODH
Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1,924,0.889057111,SU3327,JNK inhibitor,MAPK8
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,925,-1.0,vonoprazan,potassium-competitive acid antagonist,ATP4A
C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1,926,-1.0,sparteine-sulfate,,
C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2C[C@@H]3CC[C@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,927,-1.0,retapamulin,protein synthesis inhibitor,
CNCCc1ccc(O)c(O)c1,928,-1.0,deoxyepinephrine,"adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2"
N=C(N)SCCc1c[nH]cn1,929,-1.0,imetit,histamine receptor agonist,"HRH3, HRH4"
C=CCN=C=S,930,-1.0,allylisothiocyanate,TRPV agonist,TRPA1
CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,931,-1.0,alpha-linolenic-acid,omega 3 fatty acid stimulant,"ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1"
COc1cc(CCC(C)=O)ccc1O,932,-1.0,vanillylacetone,,
O=C(/C=C/c1ccc(O)cc1)c1ccc(O)cc1O,933,-1.0,isoliquiritigenin,guanylate cyclase activator,GABBR1
O/N=C/c1cc[n+](COC[n+]2ccc(/C=N/O)cc2)cc1,934,0.930851207,obidoxime,cholinesterase reactivator,ACHE
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,935,-1.0,prucalopride,serotonin receptor agonist,HTR4
CCCC(=O)O[C@@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@@]21C,936,0.803506884,difluprednate,glucocorticoid receptor agonist,NR3C1
N[C@@H](CSCC(=O)O)C(=O)O,937,-1.0,SCMC-Lys,mucolytic agent,GSTP1
C=C[C@]1(C)C[C@@H](OC(=O)CSC(C)(C)CNC(=O)[C@H](N)C(C)C)[C@@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,938,0.7748462970000001,valnemulin,bacterial 50S ribosomal subunit inhibitor,
CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,939,-1.0,lubiprostone,chloride channel activator,CLCN2
CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,940,-1.0,betamethasone-valerate,glucocorticoid receptor agonist,NR3C1
O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12,941,-1.0,cefonicid,bacterial cell wall synthesis inhibitor,
Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,942,0.6953024309999999,tanshinone-i,AP inhibitor,IFNG
CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1,943,-1.0,denatonium-benzoate,,
CN/C(=N\C#N)NCCSCc1nc[nH]c1C,944,0.8606477990000001,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2"
Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12,945,-1.0,CGP-71683,neuropeptide receptor antagonist,NPY5R
COc1cccc(OC)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,946,-1.0,methicillin,bacterial cell wall synthesis inhibitor,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,947,1.319702043,tyrphostin-AG-494,EGFR inhibitor,EGFR
COC(C)(C)CCC[C@H](C)C/C=C/C(C)=C/C(=O)OC(C)C,948,-1.0,methoprene-(s),,
CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,949,-1.0,HEMADO,,"ADORA1, ADORA2A, ADORA2B, ADORA3"
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C\CC[C@@]1(C)O[C@@H]21,950,0.920052848,parthenolide-(-),NFkB pathway inhibitor,HDAC1
CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1,951,-1.0,bunazosin,adrenergic receptor antagonist,ADRA1A
CCCCCCCC(=O)O,952,-1.0,caprylic-acid,,
CN(C)/N=N/c1[nH]cnc1C(N)=O,953,0.9522018945,dacarbazine,DNA alkylating agent,"PGD, POLA2"
CCCCCCCCCCCCN1CCCCCC1=O,954,-1.0,laurocapram,,
O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,955,0.953257523,sodium-glucoheptonate,,
C[C@H]1CN(CC(=O)Nc2ccc3c(c2)Cc2cccc(-c4cc(=O)cc(N5CCOCC5)o4)c2S3)C[C@@H](C)O1,956,-1.0,KU-60019,ATM kinase inhibitor,ATM
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)O,957,-1.0,TXA127,angiotensin receptor agonist,
CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,958,-1.0,chlorprothixene,dopamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C"
Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,959,0.823885147,broxaldine,,
CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO,960,-1.0,aceneuramic-acid,,"AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1"
N[C@H](Cc1c[nH]cn1)C(=O)O,961,-1.0,copper-histidine,,"HAL, HARS, HDC, SLC15A3, SLC15A4, SLC38A3, SLC38A5"
C=C(C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]34C(=O)O[C@H]2[C@@]41C,962,-1.0,picrotoxinin,GABA receptor antagonist,"GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B"
Nc1nc(N)nc(NC2CC2)n1,963,1.416321398,cyromazine,,
COc1cccc(/C=N/N=C/c2cccc(OC)c2)c1,964,-1.0,DMeOB,,GRM5
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,965,0.909062516,ribociclib,CDK inhibitor,"CDK4, CDK6"
CN(C)C(=S)SC(=S)N(C)C,966,0.848208726,tetramethylthiuram-monosulfide,,
COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C,967,-1.0,go-6983,protein kinase inhibitor,"PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ"
CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1,968,1.459274045,fexinidazole,,
CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C,969,-1.0,lycopene,free radical scavenger,
CCCCCCCCCCCCCCCCO,970,-1.0,1-hexadecanol,,
CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(=O)O)[C@@H]21,971,-1.0,RU-28318,cytochrome P450 inhibitor,NR3C2
CN(C)CC/C=C1/c2ccccc2COc2ccccc21,972,-1.0,doxepin,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HRH2, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, KCNH2, SLC6A2, SLC6A4"
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC,973,-1.0,tylosin,protein synthesis inhibitor,
CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,974,1.175751722,afobazole,anxiolytic,
CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(C(F)(F)F)cc(C(F)(F)F)c1,975,-1.0,"L-732,138",tachykinin antagonist,"TACR1, TACR2"
CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C2)OC(=O)C1,976,-1.0,gadodiamide,radiopaque medium,
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,977,0.863813257,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3"
CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,978,0.9268683459999999,FK-3311,cyclooxygenase inhibitor,PTGS2
C=CCN1CCN(c2nc3ccccc3nc2C#N)CC1,979,-1.0,3-AQC,serotonin receptor agonist,HTR3A
CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1,980,-1.0,thiamet-g,GLCNAC phosphotransferase inhibitor,MGEA5
N=[N+]=CC(=O)CC[C@H](N)C(=O)O,981,-1.0,diazooxonorleucine,glutamate receptor antagonist,
CCNC(=O)c1[nH]nc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1,982,0.838828218,VER-49009,HSP inhibitor,HSP90AA1
COc1cc(O)c(C(=O)c2ccccc2)cc1S(=O)(=O)O,983,-1.0,sulisobenzone,,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,984,-1.0,roxithromycin,bacterial 50S ribosomal subunit inhibitor,"ABCB1, MLNR"
CCOc1ccc(Nc2nc(-c3c(C)nc4ccccn34)cs2)cc1,985,0.641949075,JK-184,hedgehog pathway inhibitor,
CCn1c(N)c(C(=O)NC)c(=O)c2ccc(C#C[C@@](C)(O)COC)nc21,986,0.865915203,SAR131675,VEGFR inhibitor,FLT4
Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1,987,-1.0,apraclonidine,adrenergic receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C"
CN1CCN(CCCCN2C(=O)CN(/N=C/c3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,988,-1.0,azimilide,potassium channel blocker,"KCNA5, KCNE1, KCNH2, KCNQ1"
O=C(OCCN1CCOCC1)c1cccnc1Nc1cccc(C(F)(F)F)c1,989,-1.0,morniflumate,anti-inflammatory agent,
CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1,990,-1.0,octocrylene,,
O=P(O)(O)OC(CO)CO,991,-1.0,beta-glycerophosphoric-acid,,
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccccc12,992,-1.0,cinchonidine,P glycoprotein inhibitor,
COc1ccc(-n2c(C)c([N+](=O)[O-])c3ccc(O)cc32)cc1,993,-1.0,ID-8,,
Cc1ccc(S(=O)(=O)Cc2nc(-c3ccc(C(=O)NCc4cccnc4)cc3)oc2C)cc1,994,0.667775068,STF-118804,NAMPT inhibitor,NAMPT
N#CCC(=O)NN,995,-1.0,cyacetacide,,
CC(=O)Nc1ncc([N+](=O)[O-])s1,996,1.102490661,nithiamide,bacterial DNA inhibitor,
CC(C)(O)C(Cl)(Cl)Cl,997,-1.0,chlorobutanol,,
CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc21,998,1.3706931009999999,SDZ-WAG-994,adenosine receptor agonist,ADORA1
O=C(Nc1ccc(O)cc1)c1ccccc1O,999,-1.0,N-salicoylaminophenol,ribonucleotide reductase inhibitor,
O=S(=O)(O)c1ccc(-c2c3nc(c(-c4ccc(S(=O)(=O)O)cc4)c4ccc([nH]4)c(-c4ccc(S(=O)(=O)O)cc4)c4nc(c(-c5ccc(S(=O)(=O)O)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1,1000,-1.0,TPPS4,,
C[C@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1001,0.829882393,crizotinib-(S),MTH1 inhibitor,NUDT1
O=C1NC(=O)/C(=C\c2ccc(-c3ccc(F)cc3)o2)S1,1002,-1.0,CAY10505,PI3K inhibitor,PIK3CG
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N/Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1003,0.8650249529999999,eltrombopag,thrombopoietin receptor agonist,MPL
Cc1nccc2[nH]c(=O)ccc12,1004,-1.0,medorinone,,
OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,1005,1.322524678,lacitol,osmosis stimulant,
CN(C)CCCSc1ccccc1NC(=O)/C=C/c1ccccc1,1006,-1.0,cinanserin,serotonin receptor antagonist,HTR2A
O=S(=O)(O)c1ccc(O)cc1,1007,-1.0,4-phenolsulfonic-acid,,
Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,1008,1.126470719,GSK2656157,PERK inhibitor,
CCCCC[C@H](O)/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O,1009,-1.0,icomucret,mucin production enhancer,LTB4R2
C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,1010,-1.0,CUDC-101,EGFR inhibitor,"EGFR, ERBB2"
N[C@H]1CCN(O)C1=O,1011,-1.0,HA-966-(S)-(-),glutamate receptor antagonist,GRIA1
Cn1cc(/C=C2\C(=O)Nc3cccnc32)c2ccccc21,1012,1.015444677,GW-441756,growth factor receptor inhibitor,NTRK1
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(C)=O,1013,-1.0,ceramide,"phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator",
CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1014,-1.0,CB-03-01,androgen receptor antagonist,AR
Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1,1015,1.186262921,STA-5326,interleukin synthesis inhibitor,IL12A
O=C(OCCO)c1ccccc1O,1016,-1.0,2-hydroxyethyl-salicylate,,
O=c1oc2cc(O)ccc2s1,1017,1.272990963,tioxolone,carbonic anhydrase inhibitor,CA2
O=C(O)C(Cl)(Cl)Cl,1018,-1.0,trichloroacetic-acid,,
O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2,1019,0.9481073390000001,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK"
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO,1020,-1.0,anandamide,cannabinoid receptor agonist,"CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1"
CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O,1021,1.3560934230000001,satraplatin,DNA alkylating agent,
Cc1nnsc1C(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2C(F)(F)F)cc1,1022,-1.0,YM-58483,calcium channel blocker,"TRPC3, TRPC5, TRPM4"
C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,1023,1.166526806,epiandrosterone,steroid,G6PD
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,1024,0.9394653770000001,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET"
CO[C@H]1C[C@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1025,0.8501782335,temsirolimus,mTOR inhibitor,MTOR
CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,1026,0.9507063370000001,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2"
CCCCCCCC/C=C/C(=O)O,1027,-1.0,trans-2-Undecenoic-acid,,
Nc1nc(NCCNc2ncc(-n3ccnc3)c(-c3ccc(Cl)cc3Cl)n2)ccc1[N+](=O)[O-],1028,-1.0,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B"
CN(CCOP(=O)(O)O)C(=N)N,1029,-1.0,creatinol-phosphate,,
O=C1N=C(N2CCOCC2)CN1c1ccc(Cl)cc1,1030,-1.0,ADD-233089,benzodiazepine receptor agonist,
O=C(O)CCCc1c[nH]c2ccccc12,1031,-1.0,3-indolebutyric-acid,,"B2M, HLA-A, TRAC, TRBC1"
CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@]34[C@H]1[C@](O)([C@@H](OC)[C@H]23)[C@@]1(O)C[C@H](OC)[C@H]2C[C@@H]4[C@@H]1[C@H]2OC,1032,-1.0,methyllycaconitine,acetylcholine receptor antagonist,CHRNA7
OC[C@H]1O[C@@H](Oc2cc(O)cc(/C=C/c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1033,0.837736157,polydatin,ICAM1 expression inhibitor,ICAM1
CN(C)C(=O)Nc1cccc(-c2ccc(N(C)C)cc2)c1,1034,-1.0,atglistatin,adipose triglyceride lipase inhibitor,
CCC(=O)c1c(O)cc(O)cc1O,1035,-1.0,flopropione,serotonin receptor antagonist,HTR1A
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,1036,-1.0,lacidipine,calcium channel blocker,CACNA1C
CCC[C@H](NC(=O)/C(C#N)=C/c1cccc(Br)n1)c1ccccc1,1037,0.695470038,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X"
O=C(C=Cc1ccc2c(c1)OCO2)N1CCCCC1,1038,-1.0,ilepcimide,anticonvulsant,
COc1ccc(Br)cc1S(=O)(=O)NC(=O)/C=C/c1ccccc1Cc1ccc2ccccc2c1,1039,0.86696667,"L-798,106",prostanoid receptor antagonist,PTGER3
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,1040,1.427608653,hyodeoxycholic-acid,atherosclerosis formation inhibitor,
CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,1041,1.162507928,TU-2100,,
CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1,1042,-1.0,FH1,hepatocyte function enhancer,
O=C(CCCl)NCc1ccccc1,1043,-1.0,beclamide,anticonvulsant,
N=C(N)S/C=C\C(=O)O,1044,-1.0,ZAPA,,
CCC(C)(C)C(=O)O,1045,-1.0,HQK-1001,,
CN[C@@H](C)[C@H](O)c1ccccc1,1046,-1.0,ephedrine,adrenergic receptor agonist,"ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2"
CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)c3ccccc3)C(=O)N2[C@@H]1C(=O)O,1047,-1.0,mezlocillin,bacterial cell wall synthesis inhibitor,
O=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1,1048,-1.0,midafotel,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D"
COc1ccc(O)cc1,1049,-1.0,mequinol,,TYR
O=C(O)CCC(=O)O,1050,-1.0,succinic-acid,,"ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE"
CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,1051,-1.0,diethylstilbestrol,estrogen receptor agonist,"ESR1, ESR2, ESRRB, ESRRG"
CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc12,1052,-1.0,SX-011,MAP kinase inhibitor,MAPK14
COc1cc(NC(=O)c2ccccn2)ccc1Cl,1053,0.994190792,VU0361737,glutamate receptor positive allosteric modulator,GRM4
O=[N+]([O-])c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,1054,-1.0,RN-1747,TRPV agonist,TRPV4
Cc1cc(N2CCOCC2)ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1,1055,0.423188697,MPI-0479605,mitotic kinase inhibitor,TTK
CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,1056,-1.0,WZ4003,AMPK inhibitor,"NUAK1, NUAK2"
CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1,1057,-1.0,danofloxacin,bacterial DNA gyrase inhibitor,
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC,1058,-1.0,desogestrel,progesterone receptor agonist,"ESR1, PGR"
CC(C)(C)/[N+]([O-])=C/c1ccc(S(=O)(=O)O)cc1S(=O)(=O)O,1059,-1.0,NXY-059,free radical scavenger,
CCCCC/C=C\C/C=C\CCCCCCCC(=O)NCCCC(=O)O,1060,-1.0,GABA-linoleamide,benzodiazepine receptor agonist,
C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C,1061,-1.0,ethynodiol-diacetate,,"ESR1, PGR"
Nc1nc(N)c2nc(-c3cccc(O)c3)cnc2n1,1062,0.864102391,TG-100713,PI3K inhibitor,
N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,1063,-1.0,liothyronine-(isomer),,
NC1=NC(=O)N([C@H]2C[C@@H](O)[C@@H](CO)O2)CN1,1064,0.833393942,KP-1212,,
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,1065,-1.0,fesoterodine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5"
C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@H]12)[C@@](O)(CO)C3,1066,-1.0,cafestol,pregnane X receptor agonist,
COc1cc(/C=C/C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC,1067,-1.0,cinepazide,calcium channel activator,
c1ccc2c(c1)sc1ccccc12,1068,-1.0,dibenzothiophene,,
CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1,1069,-1.0,zimelidine,selective serotonin reuptake inhibitor (SSRI),"MAOA, MAOB, SLC6A4"
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3ccn4ncccc43)CS[C@H]12)c1nsc(N)n1,1070,-1.0,cefozopran,bacterial cell wall synthesis inhibitor,
Oc1ccc(Cl)c2cccnc12,1071,-1.0,cloxyquin,potassium channel activator,KCNK18
C=C1[C@@H](C)[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]23OC(=O)/C=C\[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O,1072,0.866725655,cytochalasin-b,microtubule inhibitor,ACTB
COc1ccc(-c2cc(=O)c3c(O)c(OC)c(O)cc3o2)cc1OC,1073,-1.0,eupatilin,mucus protecting agent,
O=C(NCCCN1CCC2(CC1)OCc1ccccc12)[C@H]1CCCN1Cc1ccccc1,1074,1.568400613,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1
CCCCCCCCCCCCCCCC[N+](C)(C)C,1075,0.852282223,cetrimonium,,
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,1076,-1.0,AG-490,"EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3"
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](O)(C(=O)O)C[C@@H](O)[C@H]1O,1077,1.3110308720000001,chlorogenic-acid,antioxidant,SLC37A4
C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1,1078,-1.0,DAPT,gamma secretase inhibitor,
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,1079,-1.0,icosapent,platelet aggregation inhibitor,"ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1"
CC(=O)Nc1ccc(C(=O)O)cc1,1080,-1.0,acedoben,,
O=c1ccc2cc3ccoc3cc2o1,1081,-1.0,psoralen,,"MAOA, MAOB"
CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,1082,-1.0,ecabapide,,
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,1083,-1.0,mirabegron,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3"
NC(CO)(CO)CO,1084,1.28300766,trometamol,,"AMD1, CANT1, DCN, NEIL1, VEGFA"
CN1[C@@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2,1085,-1.0,benztropine-mesylate,acetylcholine receptor antagonist,"CHRM1, HRH1, SLC6A3"
Cc1cccc(C)c1NC(=O)c1ccc(N)cc1,1086,-1.0,ameltolide,anticonvulsant,
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1087,-1.0,"6,_7-dehydro-17-acetoxy-progesterone",steroidal progestin,
CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1,1088,0.858429097,BAY-11-7085,NFkB pathway inhibitor,NFKBIA
CCCCCCCC/C=C\CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1,1089,-1.0,OMDM-2,FAAH inhibitor,GPR119
Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O,1090,-1.0,CG-400549,FABI inhibitor,
Nc1nc(=O)n([C@H]2C[C@@H](O)[C@@H](CO)O2)cc1Cl,1091,1.215277894,cytochlor,,
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,1092,-1.0,pentacosanoic-acid,,
COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,1093,1.325562394,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB"
Nc1nc(Nc2ccccc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,1094,-1.0,CV-1808,adenosine receptor agonist,ADORA2A
OC[C@H](O)[C@H](O)[C@H](O)CO,1095,0.9135785129999999,ribitol,,
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1,1096,-1.0,etofibrate,PPAR receptor agonist,PPARA
Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnc2ccc(Br)cn12,1097,0.551697059,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC"
CCc1ccc(/C=C2/SC(=S)NC2=O)cc1,1098,-1.0,10058-F4,c-Myc inhibitor,
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1099,0.814221966,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR"
C1CCC2(CC1)CCNCC2,1100,-1.0,"4,4-pentamethylenepiperidine",M2 channel blocker,
CC(C)(C(=O)O)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,1101,-1.0,carebastine,histamine receptor antagonist,HRH1
C/C(=C\c1ccc(C(=O)O)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C,1102,-1.0,TTNPB,retinoid receptor agonist,"RARA, RARB, RARG"
Cc1ccc(NC(=O)C(C)C)cc1C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1,1103,-1.0,SNAP-94847,,"ADRA1A, DRD2"
N=C(N)NCCCCN,1104,-1.0,agmatine,nitric oxide synthase inhibitor,"ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH"
CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1,1105,-1.0,NSC-9965,acetylcholine receptor antagonist,"CHRNA4, CHRNB2"
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1,1106,-1.0,cephapirin,bacterial cell wall synthesis inhibitor,
O=C(O)[C@H]1O[C@@H](Oc2cc3oc(-c4ccccc4)cc(=O)c3c(O)c2O)[C@H](O)[C@@H](O)[C@@H]1O,1107,1.282092562,baicalin,beta glucuronidase inhibitor,PREP
CCCCCCCCCCCCCCCCCCCCCCO,1108,-1.0,docosanol,lipase clearing factor inhibitor,TLR7
Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,1109,-1.0,acrivastine,histamine receptor antagonist,HRH1
COc1cc(/C=C2\CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1,1110,-1.0,E-2012,gamma secretase modulator,"APH1A, APH1B, PSENEN"
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1111,1.313416746,capsaicin,TRPV agonist,"CFTR, TRPV1"
Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O,1112,-1.0,PIK-294,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG"
NC(=O)CN1C[C@H](O)CC1=O,1113,1.1335122345,oxiracetam,acetylcholine receptor agonist,
O=S(=O)(O)NC1CCCCC1,1114,-1.0,cyclamic-acid,,
CC1=CC(=O)NS(=O)(=O)O1,1115,0.8382215270000001,acesulfame-potassium,,
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1116,1.1990828759999999,dienogest,progesterone receptor agonist,PGR
C[N+](C)(CF)CCO,1117,1.260118133,fluoromethylcholine,,
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1118,0.86626233,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1119,-1.0,dextrose,,
NCCS(=O)(=O)O,1120,0.9155466109999999,taurine,antioxidant,
CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,1121,-1.0,dapoxetine,selective serotonin reuptake inhibitor (SSRI),"HTR1A, HTR1B, HTR2C, SLC6A4"
CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO,1122,0.7441828705,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9"
O=C(O)c1cccnc1C(=O)O,1123,-1.0,quinolinic-acid,glutamate receptor agonist,
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N2CCO[C@H](OC)C2)[C@H](O)[C@H](C)O1,1124,0.38758635799999996,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A"
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1125,-1.0,bilastine,histamine receptor antagonist,HRH1
C/C=C/C/C=C/CCC(=O)[C@H]1O[C@H]1C(N)=O,1126,-1.0,cerulenin,fatty acid synthase inhibitor,FASN
O=S(=O)(O)c1cc(I)c(O)c2ncccc12,1127,-1.0,chiniofon,antiprotozoal agent,
CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O,1128,-1.0,CF102,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3"
CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,1129,-1.0,clobazam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ"
C=C(C)[C@H]1CN[C@H](C(=O)O)[C@H]1CC(=O)O,1130,-1.0,kainic-acid,kainate receptor agonist,"GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5"
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1131,-1.0,alprostadil,prostanoid receptor agonist,"CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR"
O=C(O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1,1132,-1.0,"ICI-215,001",adrenergic receptor agonist,ADRB3
CC(=O)NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O,1133,-1.0,N-acetylcarnosine,,
Nc1cccc2c(=O)[nH][nH]c(=O)c12,1134,-1.0,monosodium-alpha-luminol,,
O=C(O)/C=C/c1c[nH]cn1,1135,-1.0,cis-urocanic-acid,serotonin receptor agonist,HTR2A
C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,1136,0.079527574,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B"
O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1,1137,-1.0,ozagrel,thromboxane synthase inhibitor,TBXAS1
O=C(/C=C/c1ccc(O)c(O)c1)O[C@@H]1C[C@](OC(=O)/C=C/c2ccc(O)c(O)c2)(C(=O)O)C[C@@H](O)[C@H]1O,1138,-1.0,"1,5-dicaffeoylquinic-acid",,
CCCCC/C=C\C[C@@H](O)/C=C/C=C/C=C\[C@@H](O)CCCC(=O)O,1139,-1.0,LTB4,leukocyte activator,"LTB4R, LTB4R2"
CC(=O)N[C@@H](Cc1ccccc1)C(=O)O,1140,-1.0,afalanine,dopamine receptor agonist,DRD2
Clc1ccc(-c2nc3sccn3c2/C=N/OCc2ccc(Cl)c(Cl)c2)cc1,1141,-1.0,CITCO,constitutive androstane receptor (CAR) agonist,NR1I3
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,1142,-1.0,acadesine,AMPK activator,
COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,1143,-1.0,fluvoxamine,selective serotonin reuptake inhibitor (SSRI),SLC6A4
CCC(CC)(CC(=O)Nc1cccc(/C=C/c2nc(C3CCC3)cs2)c1)C(=O)O,1144,0.939681344,cinalukast,leukotriene receptor antagonist,CYSLTR1
COc1ccc(C(=O)CCC(=O)O)c2ccccc12,1145,-1.0,menbutone,,
CC(C)C(N)=O,1146,-1.0,isobutyramide,gene expression stimulant,"HBE1, HBG1"
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@@]21C,1147,-1.0,dichlorisone-acetate,,
O=C(C[C@H]1NCCC[C@@H]1O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,1148,0.5982162870000001,halofuginone,collagenase inhibitor,"COL1A1, MMP2"
N#CSc1cc(SC#N)c(N)nc1N,1149,0.8518722209999999,PR-619,DUB inhibitor,
CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1,1150,-1.0,propacetamol,cyclooxygenase inhibitor,PTGS2
OCCSCCO,1151,-1.0,thiodiglycol,,
CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,1152,-1.0,dosulepin,"norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4"
O=C(O)CCc1nc2ccccc2[nH]1,1153,-1.0,procodazole,immunostimulant,
N[C@@H](CSCCCO)C(=O)O,1154,0.980888903,fudosteine,mucolytic agent,
CCOC(=O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1,1155,-1.0,efloxate,vasodilator,
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1,1156,0.823338211,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Nc1ccc(O)cc1,1157,-1.0,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1"
CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,1158,-1.0,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP
CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,1159,-1.0,penbutolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B"
COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c1-2,1160,-1.0,BMS-806,HIV attachment inhibitor,
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,1161,1.5167155319999999,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB"
Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,1162,-1.0,oxiconazole,bacterial cell wall synthesis inhibitor,
O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,1163,-1.0,benznidazole,DNA synthesis inhibitor,
COc1cc(-c2ccc(/N=N/c3ccc4c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c4c3O)c(OC)c2)ccc1/N=N/c1ccc2c(S(=O)(=O)O)cc(S(=O)(=O)O)c(N)c2c1O,1164,-1.0,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF
CO/N=C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1,1165,-1.0,cefpirome,bacterial cell wall synthesis inhibitor,
O=C(c1ccc(F)cc1)N1CCC[C@H](c2nc(-c3ccc(F)cc3)no2)C1,1166,-1.0,ADX-47273,glutamate receptor modulator,GRM5
CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,1167,1.141270245,clofazimine,GK0582 inhibitor,
O=C(O)CCCNC(=O)c1cccnc1,1168,-1.0,pikamilone,,
O=[N+]([O-])c1ccc([As](=O)(O)O)cc1,1169,1.222990712,nitarsone,,
COC(=O)N/N=C/c1c[n+]([O-])c2ccccc2[n+]1[O-],1170,-1.0,carbadox,other antibiotic,
C=COCC(F)(F)F,1171,1.292014237,fluroxene,local anesthetic,
O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,1172,0.833663753,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1173,-1.0,dabigatran-etexilate,thrombin inhibitor,F2
CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)Nc5nccs5)CC4)c(Cl)cnc3[nH]2)cc1,1174,0.844403564,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC"
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,1175,0.6586489855,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4"
C/C=C/C(=O)N(CC)c1ccccc1C,1176,-1.0,crotamiton,antipruritic,
COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]2C(CO)=CC[C@H]12,1177,-1.0,geniposide,GLP receptor agonist,GLP1R
[N-]=[N+]=N[C@]1(CO)O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O,1178,0.9138233459999999,Ro-9187,HCV inhibitor,
O=C1CC[C@@H](C(=O)O)N1,1179,-1.0,pidolic-acid,,"ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA"
CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C\[C@H](CC)[C@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]3O)C(C)=C/C(C)=C/C[C@H]([C@@H](C)O)OC2=O)O[C@@H]1C,1180,-1.0,fidaxomicin,RNA polymerase inhibitor,
CCc1c(C(=O)NCCc2ccc(N3CCCCC3)cc2)[nH]c2ccc(Cl)cc12,1181,-1.0,org-27569,cannabinoid receptor modulator,CNR1
O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,1182,-1.0,olsalazine,cyclooxygenase inhibitor,"IFNG, TPMT"
N[C@@H]1CCN(O)C1=O,1183,-1.0,HA-966-(R)-(+),glutamate receptor agonist,GRIA1
C=C(NC(=O)C(=C)NC(=O)c1csc(C2=N[C@@H]3c4csc(n4)[C@H]4NC(=O)c5csc(n5)[C@H]([C@](C)(O)[C@@H](C)O)NC(=O)[C@H]5CSC(=N5)/C(=C/C)NC(=O)[C@H]([C@@H](C)O)NC(=O)c5csc(n5)[C@]3(CC2)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)N[C@@H]2C=Cc3c([C@H](C)O)cc(nc3[C@H]2O)C(=O)O[C@@H]4C)n1)C(N)=O,1184,-1.0,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1
CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2,1185,-1.0,hesperadin,Aurora kinase inhibitor,AURKB
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1186,-1.0,dapagliflozin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A2"
CCN(CC)c1ccc(/C=N/NC(=O)c2ccc(O)cc2)cc1,1187,-1.0,DY131,estrogen-related receptor agonist,"ESRRB, ESRRG"
Nc1ccc(C(=O)O)cc1,1188,-1.0,potassium-p-aminobenzoate,,
O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,1189,0.5603504435,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT
CC(=O)Oc1c(C)cccc1C(=O)O,1190,-1.0,cresopirine,,
CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1,1191,0.599506651,NMS-E973,HSP inhibitor,
O=C(O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1,1192,-1.0,bentiromide,,HPN
Oc1ccnc(S)n1,1193,-1.0,2-thiouracil,,
CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(=O)O,1194,-1.0,glutathione-monoisopropyl-ester,lipid peroxidase inhibitor,
OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl,1195,-1.0,sucralose,,
Cc1oc(=O)oc1COC(=O)C1=C([C@H]2CCCO2)S[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12,1196,-1.0,faropenem-medoxomil,lactamase inhibitor,
O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1,1197,-1.0,tarafenacin,acetylcholine receptor antagonist,CHRM3
CC(C)[C@@H](N)C(=O)O,1198,-1.0,val,,"BCAT1, PCCB, VARS"
O=C(O)CC/C=C\C[C@@H]1CO[C@H](c2ccccc2Cl)O[C@@H]1c1ccccc1O,1199,-1.0,ICI-192605,thromboxane receptor antagonist,TBXA2R
CC(C)(C)c1cc(/C=C(\C#N)C(N)=S)cc(C(C)(C)C)c1O,1200,-1.0,tyrphostin-AG-879,tyrosine kinase inhibitor,"ERBB2, KDR, NTRK1"
O=C(/C=C/C=C/c1ccc2c(c1)OCO2)N1CCCCC1,1201,0.8975069179999999,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1"
N[C@@H](CSS(=O)(=O)O)C(=O)O,1202,-1.0,S-Sulfo-L-cysteine-sodium-salt,glutamate receptor agonist,
C[N+](C)(C)C[C@H](O)CC(=O)O,1203,1.263617989,levocarnitine,,
CCCCCCCCCCCCc1ccc(S(=O)(=O)Nc2nncs2)cc1,1204,-1.0,PHT-427,"AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1"
CN(C)/N=N/c1ccc(C(=O)O)cc1,1205,1.2261452609999999,CB-10-277,DNA synthesis inhibitor,
NCC(=O)CCC(=O)OCc1ccccc1,1206,-1.0,aminolevulinic-acid-benzyl-ester,,
CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,1207,0.321177799,crystal-violet,other antibiotic,
CC(=N)NCCCC[C@H](N)C(=O)O,1208,-1.0,L-NIL,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3"
C=CCc1cc(OC)c(O)c(C(=O)NCCO)c1,1209,-1.0,alibendol,antispasmodic,
OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O,1210,-1.0,N6-cyclopentyladenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1"
N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,1211,0.87080186,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR
NCCCCCC(O)(P(=O)(O)O)P(=O)(O)O,1212,-1.0,neridronic-acid,bone resorption inhibitor,FDPS
CCN(CC)c1ccc(C(=C2C=CC(=[N+](CC)CC)C=C2)c2ccccc2)cc1,1213,0.536985485,brilliant-green,,
NCc1cc(O)no1,1214,-1.0,muscimol,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3"
Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,1215,0.849021318,chlormidazole,fungal lanosterol demethylase inhibitor,
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1216,0.7404163229999999,paricalcitol,vitamin D receptor agonist,VDR
CCOCCOc1ccccc1C(N)=O,1217,-1.0,etosalamide,anti-inflammatory agent,
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,1218,-1.0,laquinimod,immunosuppressant,CXCL2
COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O,1219,-1.0,neohesperidin-dihydrochalcone,,
COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1O,1220,0.61390168,combretastatin-A-4,tubulin polymerization inhibitor,
CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,1221,-1.0,eslicarbazepine-acetate,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A"
Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,1222,-1.0,FPH1-(BRD-6125),hepatocyte function enhancer,
O=C(O)CC(=O)C(=O)O,1223,-1.0,oxaloacetate,glutamate release inhibitor,"CS, SPR"
Cc1ccc2c(c1)C(=O)[C@]1(O)CCN(c3ccccc3)C1=N2,1224,1.266823903,blebbistatin-(-),ATPase inhibitor,
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,1225,-1.0,naratriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F"
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,1226,0.426271134,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1227,-1.0,esomeprazole,ATPase inhibitor,ATP4A
COc1cccc(NC(=O)/C=C/c2ccc(Cl)cc2)c1,1228,1.1714148340000001,SB-366791,TRPV antagonist,TRPV1
N[C@H](C(=O)O)c1ccc(O)c(C(=O)O)c1,1229,-1.0,3-carboxy-4-hydroxyphenylglycine-(S),glutamate receptor antagonist,"GRM1, GRM5"
O/N=C/c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O,1230,-1.0,FERb-033,EGFR inhibitor,ERBB2
Cn1cccc1/C=C1\C(=O)NC(=O)c2ccccc21,1231,-1.0,BYK-204165,PARP inhibitor,PARP1
Nc1cc(F)ccc1NC(=O)/C=C/c1cnn(C/C=C/c2ccccc2)c1,1232,1.308453187,RGFP966,HDAC inhibitor,HDAC3
O=C1c2ccccc2C(=O)C1c1ccc(Cl)cc1,1233,-1.0,chlorindione,,
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1234,-1.0,tenofovir-disoproxil,nucleoside reverse transcriptase inhibitor,CYP1A2
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC,1235,-1.0,doconexent-ethyl-ester,omega 3 fatty acid stimulant,
CO/N=C1/C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C,1236,-1.0,moxidectin,chloride channel antagonist,
COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,1237,-1.0,acitretin,retinoid receptor agonist,"RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3"
N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1,1238,-1.0,hydroxystilbamidine,,
C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1239,-1.0,dihydroartemisinin,antimalarial agent,
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1240,0.7490724759999999,deforolimus,mTOR inhibitor,MTOR
Cc1ccc(S(N)(=O)=O)cc1,1241,-1.0,para-toluenesulfonamide,,"CA12, CA2, CA6, CA9"
CN[C@H](CC(=O)O)C(=O)O,1242,-1.0,NMDA,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D"
COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1,1243,-1.0,GR125487,serotonin receptor antagonist,HTR4
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,1244,1.077671459,aztreonam,bacterial cell wall synthesis inhibitor,
CC(=O)c1ccc2c(c1)[C@@H]1C=CC[C@@H]1[C@H](c1cc3c(cc1Br)OCO3)N2,1245,-1.0,G-1,G protein-coupled receptor agonist,GPER1
N=C(N)N/N=C/c1c(Cl)cccc1Cl,1246,-1.0,guanaben-acetate,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C"
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1247,0.8511531059999999,cholecalciferol,,VDR
C[C@H]1CN(c2c(F)c(F)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1,1248,-1.0,orbifloxacin,bacterial DNA gyrase inhibitor,
CSC[C@H](N)C(=O)O,1249,1.098136194,S-methylcysteine,,"CTSD, MGMT"
CS/C(N)=C(C#N)/C(C#N)=C(\N)SC,1250,-1.0,U-0124,MEK inhibitor,
CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O,1251,-1.0,orlistat,lipase inhibitor,"CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP"
Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,1252,0.9345322855,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET"
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2,1253,0.7959038940000001,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2"
O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1,1254,-1.0,AS-604850,PI3K inhibitor,"PIK3CA, PIK3CG"
C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc21,1255,1.417460969,2'-MeCCPA,adenosine receptor agonist,ADORA1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1256,-1.0,epoprostenol,prostacyclin analog,"P2RY12, PTGER1, PTGER4, PTGIR, PTGIS"
Cc1[nH]c2ccc(O)cc2c1CCN,1257,-1.0,2-methyl-5-hydroxytryptamine,serotonin receptor agonist,"HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6"
c1ccc2sc(SNC3CCCCC3)nc2c1,1258,-1.0,"CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide",,
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,1259,1.212427402,ulipristal,progesterone receptor antagonist,PGR
CNCCc1cnc[nH]1,1260,-1.0,N-alpha-Methylhistamine-dihydrochloride,histamine receptor agonist,HRH4
CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,1261,-1.0,zotepine,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4"
Cc1c(C)c2c(c(C)c1OC(=O)CCC(=O)O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1262,-1.0,D-alpha-tocopheryl-succinate,,
CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12,1263,-1.0,nedocromil,histamine receptor antagonist,"CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR"
Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,1264,1.018423712,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR"
CN1[C@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@@H]1O[C@@H]12,1265,-1.0,scopolamine,acetylcholine receptor antagonist,
CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O,1266,-1.0,NPC-15199,ICAM1 antagonist,PPARG
CCC(=O)O[C@@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@@]21C,1267,1.194197959,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B"
COc1c(C)c(C(=O)c2ccc(N)c(C(=O)O)c2)n2ccccc12,1268,-1.0,SSR128129E,,
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1,1269,-1.0,tandospirone,serotonin receptor agonist,HTR1A
O=C(O)[C@H]1CN(CCCP(=O)(O)O)CCN1,1270,0.840157358,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D"
Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,1271,0.803636847,TMC-353121,RSV fusion inhibitor,
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1272,0.64453323,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4"
CCNC(=O)/C=C/c1cccc(Br)c1,1273,-1.0,cinromide,,
CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1274,0.79788857,fluvastatin,HMGCR inhibitor,HMGCR
NC1(C(=O)O)CC1,1275,-1.0,ACPC,glutamate receptor antagonist,
O=C(Nc1cccc(Cl)c1)c1ccccn1,1276,0.86771023,VU0364770,glutamate receptor positive allosteric modulator,GRM4
N[C@H](Cc1ccc(I)cc1)C(=O)O,1277,-1.0,4-iodo-L-phenylalanine,,DPP4
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,1278,-1.0,voglibose,glucosidase inhibitor,MGAM
CCCCCCCC/C=C\CCCCCCCC(=O)NCCO,1279,1.150969594,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA"
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](/N=C/N3CCCCCC3)[C@H]2SC1(C)C,1280,-1.0,pivmecillinam,bacterial cell wall synthesis inhibitor,
O=C(O)c1ccc(N2C(=O)/C(=C/c3ccc(-c4ccc([N+](=O)[O-])cc4)o3)C=C2c2ccccc2)cc1,1281,1.36639713,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1"
Nc1nc2c(ccc3ccccc32)s1,1282,-1.0,SKA-31,potassium channel activator,KCNN4
OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,1283,1.437526881,GDC-0879,RAF inhibitor,BRAF
COc1cc(O)c2c(c1)C(=O)c1cc(C)cc(O)c1C2=O,1284,0.9071577690000001,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1
CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,1285,-1.0,lisuride,dopamine receptor agonist,"ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6"
CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,1286,1.189648813,eprosartan,angiotensin receptor antagonist,AGTR1
CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,1287,-1.0,terbinafine,fungal squalene epoxidase inhibitor,SQLE
C/C(=C\c1csc(C)n1)[C@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1,1288,0.362240534,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B"
O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1ccc(O)cc1,1289,-1.0,nifuroxazide,bacterial DNA inhibitor,
CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,1290,0.573978054,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9"
Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1,1291,0.614787389,EVP4593,NFkB pathway inhibitor,
CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,1292,-1.0,spaglumic-acid,glutamate receptor antagonist,GRM3
Nc1ccc2cc3ccc(N)cc3nc2c1,1293,0.835823161,proflavine-hemisulfate,topical anesthetic,F2
CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC1(C(=O)NC(c2ccc(F)cc2)c2ccc(F)cc2)CCCC1,1294,-1.0,MM-102,WDR5/MLL interaction inhibitor,
Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,1295,-1.0,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC"
O[C@H]([C@@H]1CO1)[C@@H](O)[C@H]1CO1,1296,0.7987028429999999,dianhydrogalactitol,DNA alkylating agent,
NCc1cccnc1,1297,-1.0,picolamine,,
NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl,1298,-1.0,azosemide,electrolyte reabsorption inhibitor,"SLC12A1, SLC12A2"
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1,1299,-1.0,pafuramidine,DNA synthesis inhibitor,
O=C(COc1ccc(C(=O)c2ccccc2)cc1)NC1CCN(Cc2ccccc2)CC1,1300,-1.0,adiporon,adiponectin receptor agonist,"ADIPOR1, ADIPOR2"
C/C=C(\C)C(=O)N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@H]3[C@](C)(C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](O)C[C@H]1OC[C@]13OC(C)=O,1301,0.47896826200000003,cephalomannine,DNA polymerase inhibitor,
COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1,1302,-1.0,omeprazole-sulfide,ATPase inhibitor,
N[Pt](N)(Cl)Cl,1303,0.9186849359999999,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP
Cc1c(I)c(=O)n(-c2ccccc2)n1C,1304,-1.0,iodoantipyrine,,
C[n+]1cccc(C(=O)O)c1,1305,-1.0,trigonelline,,
N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,1306,-1.0,glutathione,antioxidant,"ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12"
O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1,1307,-1.0,trospium,acetylcholine receptor antagonist,CHRM1
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1308,-1.0,montelukast,leukotriene receptor antagonist,"ALOX5, CYSLTR1"
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1309,1.333816015,tacrolimus,calcineurin inhibitor,FKBP1A
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,1310,0.8076704055,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3"
C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,1311,-1.0,flurbiprofen-(S)-(+),cyclooxygenase inhibitor,"PTGS1, PTGS2"
NC(=O)c1[nH]cnc1O,1312,-1.0,SM-108,,
OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O,1313,-1.0,2-chloro-N6-cyclopentyladenosine,adenosine receptor agonist,"ADORA1, ADORA2A, ADORA2B, ADORA3"
O=C1NC(=O)/C(=C\c2cccc(C(F)(F)F)c2)S1,1314,1.031230151,SMI-4a,Pim kinase inhibitor,PIM1
Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1,1315,0.955971922,INH1,Hec1 inhibitor,NDC80
CCCCN(Cc1ccc(C(=O)NO)cc1)C(=O)Nc1ccccc1,1316,1.347853345,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6"
OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1317,-1.0,flupentixol,dopamine receptor antagonist,"ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A"
CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,1318,0.903105235,ranitidine,histamine receptor antagonist,HRH2
COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,1319,0.733882115,HMN-214,PLK inhibitor,PLK1
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/NC(=O)c2ccccc2)CC[C@@]3(O)[C@H]1C5,1320,-1.0,naloxone-benzoylhydrazone,opioid receptor antagonist,"OPRK1, OPRM1"
NC(=O)N/N=C/c1ccc(Oc2ccc(F)cc2)cc1,1321,-1.0,co-102862,,"SCN4A, SCN9A"
N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1,1322,-1.0,luliconazole,sterol demethylase inhibitor,
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1,1323,-1.0,cefixime,bacterial cell wall synthesis inhibitor,
COc1cc(-c2ncn(/C=C\C(=O)OC(C)C)n2)cc(C(F)(F)F)c1,1324,0.600423746,KPT-185,exportin antagonist,XPO1
CCN(CC)CCNC(=O)c1ccccc1I,1325,-1.0,I-BZA2,,
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@@H]2CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,1326,0.478858645,epothilone-a,microtubule stabilizing agent,
O=C(O)c1ccc(/C=C2/SC(=S)N(c3cccc(C(F)(F)F)c3)C2=O)cc1,1327,-1.0,CFTRinh-172,chloride channel blocker,CFTR
Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)[C@H]2c1c(O)cc(O)c2c1O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2,1328,-1.0,procyanidin-b-2,,
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,1329,1.167268235,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,
COC(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)c1ccc(C)cc1,1330,0.990375727,TAME,,
O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12,1331,1.228127331,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH"
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3ccc(=N)n3CCO)CS[C@H]12)c1csc(N)n1,1332,-1.0,cefoselis,bacterial cell wall synthesis inhibitor,
NCC(=O)O,1333,-1.0,AZD4282,glutamate receptor antagonist,"AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9"
S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,1334,-1.0,sulbentine,other antifungal,
O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2Cl)c(Cl)c1)c1ccccn1,1335,-1.0,VU0364439,glutamate receptor positive allosteric modulator,GRM4
CCCCCCOc1nsnc1C1=CCCN(C)C1,1336,0.884829564,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7"
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,1337,-1.0,telaprevir,HCV inhibitor,"CTSA, PGR"
CC1(C)CCC[C@@]2(C)[C@H]1CC[C@@]1(C)OC(=O)C[C@H]21,1338,-1.0,sclareolide,other antifungal,
CC(C)(C)c1ccc(-c2nc3ccccc3[nH]2)cc1,1339,0.9158418970000001,ZLN005,,
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,1340,0.633211282,SNX-5422,HSP inhibitor,HSP90AA1
CC(=O)CC(=O)O,1341,-1.0,lithium-acetoacetate,,
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CC[C@@H](O)C(C)C)C[C@@H](O)C[C@@H]1O,1342,0.76878488,tacalcitol,vitamin D receptor agonist,VDR
COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1,1343,-1.0,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN"
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCO)cc23)c1,1344,0.8478356309999999,OSI-420,EGFR inhibitor,EGFR
CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(=O)N(C)C)ccc32)c2ccccc2)c1,1345,-1.0,BIX-02189,MEK inhibitor,"MAP2K5, MAPK7"
OCc1cncc(F)c1,1346,-1.0,5-fluoro-3-pyridyl-methanol,,
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,1347,-1.0,bekanamycin,bacterial 30S ribosomal subunit inhibitor,
N[Pt]1(N)OCC(=O)O1,1348,-1.0,nedaplatin,DNA inhibitor,
CCCCOC(=O)c1ccccc1C(=O)OCCCC,1349,-1.0,dibutyl-phthalate,,TRPA1
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(OCCO)c(OCCO)c4)oc4cc(OCCO)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,1350,-1.0,troxerutin,antioxidant,
CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,1351,1.225040165,nizatidine,histamine receptor antagonist,HRH2
O=C(O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]2C(CO)=CC[C@H]12,1352,-1.0,geniposidic-acid,cyclooxygenase inhibitor,
CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,1353,-1.0,difloxacin,bacterial DNA gyrase inhibitor,
CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12,1354,0.984668083,naftifine,fungal squalene epoxidase inhibitor,SQLE
CC(=O)O[Hg]c1ccccc1,1355,0.9310427370000001,phenylmercuric-acetate,other antifungal,
C[Se]C[C@H](N)C(=O)O,1356,1.2805240009999999,se-methylselenocysteine,,
O=C(O)C(=O)Nc1cccc(-c2nnn[nH]2)c1,1357,-1.0,acitazanolast,mediator release inhibitor,
Cc1ccc(OC[C@@H](O)[C@H](C)NC(C)C)c2c1CCC2,1358,-1.0,"ICI-118,551",adrenergic receptor antagonist,"ADRB2, ADRB3"
C[Se]CC[C@H](N)C(=O)O,1359,-1.0,selenomethionine,,
O=C(O)C1CCC(c2cc3cccnc3c(-c3cccc(F)c3)n2)CC1,1360,-1.0,"trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid",,
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(C)C)c1ccccc1CC2,1361,-1.0,tiracizine,sodium channel blocker,SCN5A
O=C(O)c1cc2ccccc2s1,1362,-1.0,BL-5583,hypercalcaemic agent,
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)N1CC(F)(F)C1,1363,0.701768622,KPT-276,exportin antagonist,XPO1
CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N,1364,-1.0,NPS-2143,calcium receptor antagonist,CASR
Cc1[nH]c(/C=C2/C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,1365,1.1378022140000001,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR
CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21,1366,-1.0,scopine,,
CO[C@H]1CC[C@H](N(c2cc(C3=CCCCC3)sc2C(=O)O)C(=O)[C@H]2CC[C@H](C)CC2)CC1,1367,-1.0,VCH-916,HCV inhibitor,
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1368,0.892101798,pitavastatin,HMGCR inhibitor,HMGCR
N=C(N)N,1369,1.228075205,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1"
Clc1ccc(N/N=C(\c2ccccc2)c2ccccn2)nc1,1370,0.8530596359999999,JIB04,histone lysine demethylase inhibitor,KDM4E
COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,1371,0.7370697239999999,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR"
Nc1ccc(/N=N/c2ccccc2)c(N)n1,1372,-1.0,phenazopyridine,local anesthetic,SCN1A
NC(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1,1373,-1.0,nitromide,,
NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,1374,0.999996799,CCT128930,AKT inhibitor,"PKIA, PRKACA"
N[C@@H](C(=O)O)c1ccc(O)c(C(=O)O)c1,1375,-1.0,3-carboxy-4-hydroxyphenylglycine-(R),glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C"
CN1C(=O)N(C)C2C1N(C)C(=O)N2C,1376,-1.0,mebicar,anxiolytic,
O=[N+]([O-])NC1=NCCN1Cc1ccc(Cl)nc1,1377,-1.0,imidacloprid,acetylcholine receptor antagonist,CHRFAM7A
N=C(N)NCCC[C@@H](N)C(=O)O,1378,-1.0,L-Arginine,nitric oxide precursor,"ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4"
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,1379,-1.0,triazolam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO"
COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,1380,0.914790033,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2
O=C1c2ccccc2-n2c1nc1ccccc1c2=O,1381,0.798767263,tryptanthrin,cyclooxygenase inhibitor,IDO1
Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1,1382,-1.0,AY-9944,hedgehog pathway modulator,
CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(=O)O)cc1,1383,-1.0,phthalylsulfacetamide,,
O=S(=O)(O)Oc1ccc(C(c2ccc(OS(=O)(=O)O)cc2)c2ccccn2)cc1,1384,-1.0,sodium-picosulfate,,
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1385,-1.0,lactulose,laxative,
Nc1ncnc2c1ncn2CCOCP(=O)(O)O,1386,-1.0,adefovir,DNA polymerase inhibitor,
C[N@+]12CCCC[C@@H]1CCC(=C(c1cccs1)c1cccs1)C2,1387,-1.0,tiquizium,acetylcholine receptor antagonist,
Cc1cccc(Cc2c[nH]cn2)c1C,1388,-1.0,detomidine,adrenergic receptor agonist,ADRA2A
COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,1389,0.49706654899999997,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1"
Nc1nccc2c1ncn2[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,1390,0.746836809,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2
CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,1391,-1.0,azatadine,histamine receptor antagonist,HRH1
C[C@H]1CCC/C=C/[C@@H]2C[C@H](O)C[C@H]2[C@H](O)/C=C/C(=O)O1,1392,0.6354141729999999,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2"
NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,1393,-1.0,U-104,carbonic anhydrase inhibitor,"CA1, CA12, CA2, CA9"
Cn1cc(-c2ccc3ncc(Cc4ccc5ncccc5c4)n3n2)cn1,1394,1.108623474,NVP-BVU972,MET inhibitor,MET
Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,1395,0.8193958370000001,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA"
[O-][n+]1cccc(CO)c1,1396,-1.0,mepiroxol,,
Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,1397,0.8775367690000001,PF-4981517,cytochrome P450 inhibitor,CYP3A4
Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2,1398,-1.0,hematoxylin,,
O=C(N/N=C/c1ccccc1O)c1ccccc1O,1399,1.930998885,SCS,,
COC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)c1cccc2ccccc12,1400,-1.0,SB-328437,CCR antagonist,
COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,1401,-1.0,barnidipine,calcium channel blocker,
CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1402,0.534094868,pentagastrin,CCK receptor agonist,CCKBR
CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1,1403,-1.0,SB-590885,RAF inhibitor,BRAF
O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1,1404,-1.0,SB-742457,serotonin receptor antagonist,HTR6
O=[N+]([O-])c1cncn1CCN1CCOCC1,1405,1.109956224,nimorazole,bacterial DNA inhibitor,
CON,1406,-1.0,methoxyamine,DNA repair enzyme inhibitor,APEX1
OC[C@H](O)[C@H](O)CO,1407,1.240287039,erythritol,,
CC(=O)N[C@@H](CSC/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(=O)O,1408,-1.0,acetyl-farnesyl-cysteine,methyltransferase inhibitor,PPARG
O=C1C(Cl)=C(N2CCOCC2)C(=O)N1c1ccc(Cl)c(Cl)c1,1409,1.1774630659999998,RI-1,,RAD51
OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,1410,1.175520082,inosine,neurotrophic agent,"PARP1, PNP"
Cc1cccc(C)c1NC(=O)/N=C1/CCCN1C,1411,1.193461297,xilobam,,
N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O,1412,-1.0,UBP-302,glutamate receptor antagonist,GRIK1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,1413,-1.0,retinaldehyde,,
O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,1414,-1.0,phenolsulfonphthalein,,
CNCC/C=C/c1cccnc1,1415,-1.0,rivanicline,acetylcholine receptor agonist,"CHRNA4, CHRNB2, CXCL8"
CCCCCC/C=C/C=C\CCCCCCCC(=O)O,1416,-1.0,"cis-9,trans-11-Conjugated-linoleic-acid",,
C[C@@H](N)Cc1c[nH]cn1,1417,-1.0,alpha-methylhistamine-dihydrobromide-(R)-(-),histamine receptor agonist,HRH3
NCCCCCNCC12CC3CC(CC(C3)C1)C2,1418,-1.0,IEM1754,glutamate receptor antagonist,GRIA1
Oc1ccnc(O)n1,1419,1.0324397570000001,uracil,,"DPYD, UCKL1"
Nc1ccncc1N,1420,-1.0,amifampridine,potassium channel blocker,
CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO,1421,-1.0,N-acetyl-D-glucosamine,,"B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP"
COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,1422,-1.0,AZ191,DYRK inhibitor,DYRK1B
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,1423,1.1997962229999999,INC-280,c-Met inhibitor,MET
CCOc1ccc(N=C(C)Nc2ccc(OCC)cc2)cc1,1424,-1.0,phenacaine,local anesthetic,
NC(=O)c1ccccc1O,1425,-1.0,salicylamide,analgesic agent,
COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C,1426,-1.0,leucylleucine-methyl-ester,,
Cc1ccc(/C=C2\CNC/C(=C\c3ccc(C)cc3)C2=O)cc1,1427,0.9090999340000001,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7"
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,1428,-1.0,dantrolene,calcium channel blocker,"RYR1, RYR3"
Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,1429,-1.0,zomepirac,prostaglandin synthesis inhibitor,PTGDR2
O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,1430,0.97023991,tideglusib,glycogen synthase kinase inhibitor,GSK3B
[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3/C[C@@H](O)C[C@H](O)C3=C)CCC[C@]12C)C([2H])([2H])[2H],1431,0.7749971240000001,maxacalcitol,vitamin D receptor agonist,VDR
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,1432,0.714658101,tanespimycin,HSP inhibitor,HSP90AA1
C/C(=N\NC(=O)[C@@H]1C(=O)NC[C@H]1c1ccccc1)c1cccc(Br)c1,1433,0.8582788029999999,AC-264613,PAR agonist,F2RL1
Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,1434,-1.0,CK-636,actin related protein inhibitor,"ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5"
OCc1ccc(O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,1435,1.4039802469999998,gastrodin,,
CCSC(=N)N,1436,-1.0,EIT-hydrobromide,nitric oxide synthase inhibitor,"NOS2, NOS3"
Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1,1437,-1.0,NKP-1339,HSP inhibitor,
CN(C)CCS,1438,0.909256101,captamine,,
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O,1439,-1.0,dinoprost,prostacyclin analog,"PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R"
C=CC(=O)Nc1cccc(Sc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)c1,1440,0.6889180090000001,WZ8040,EGFR inhibitor,EGFR
Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,1441,0.571630874,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC"
Fc1cccc(/C=N/N=C/c2cccc(F)c2)c1,1442,-1.0,DFB,glutamate receptor agonist,GRM5
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,1443,-1.0,2-hydroxyflutamide,androgen receptor antagonist,AR
CCOc1cc(C=O)ccc1O,1444,-1.0,ethyl-vanillin,,
Nc1c(CC(=O)O)cccc1C(=O)c1ccccc1,1445,0.953553676,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2"
O=C(O)CCNC(=O)c1ccccc1,1446,-1.0,betamipron,panipenem uptake inhibitor,
O=C(O)CCCO,1447,-1.0,sodium-oxybate,benzodiazepine receptor agonist,"GABRB1, HCAR1, SLC52A2"
Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,1448,1.242763912,pyritinol,,
C[C@@H]([C@H](O)c1ccccc1)N(C)C,1449,-1.0,"N-methyl-(-)ephedrine-[1r,2s]",,
CNCC(=O)c1ccc(O)c(O)c1,1450,-1.0,adrenalone,adrenergic receptor agonist,ADRA1A
N=C(Nc1ccc(I)cc1)NC1C2CC3CC(C2)CC1C3,1451,-1.0,IPAG,,
O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H]1OC(=O)c1cccnc1)c1cccnc1,1452,-1.0,inositol-hexanicotinate,,
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,1453,0.923940237,daclatasvir,HCV inhibitor,
Clc1cccc(/C=N/N=C/c2cccc(Cl)c2)c1,1454,-1.0,"3,3'-dichlorobenzaldazine",glutamate receptor allosteric ligand,GRM5
C=C1/C(=C/C=C2\CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1455,0.829063769,doxercalciferol,vitamin D receptor agonist,VDR
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1456,-1.0,rosuvastatin,HMGCR inhibitor,HMGCR
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC(=O)c3ccco3)CS[C@H]12)c1csc(N)n1,1457,-1.0,ceftiofur,bacterial cell wall synthesis inhibitor,
c1ccc(Oc2cccnc2)cc1,1458,1.285458095,CI-844,,
O=C(Nc1ccccc1)c1ccccc1O,1459,-1.0,salicylanilide,other antibiotic,
C[C@@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,1460,-1.0,dimethindene-(S)-(+),acetylcholine receptor antagonist,HRH1
Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,1461,-1.0,pilsicainide,sodium channel blocker,SCN5A
Oc1ccnc2cc(Cl)ccc12,1462,-1.0,chloroxoquinoline,,
CCC1(CC)C(=O)NC(=O)NC1=O,1463,-1.0,barbital,sedative,"CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2"
COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,1464,-1.0,sinomenine,angiogenesis inhibitor,
OC[C@@H](O)CN1CCN(c2ccccc2)CC1,1465,-1.0,levodropropizine,antitussive,
CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,1466,-1.0,entacapone,catechol O methyltransferase inhibitor,COMT
C[C@](N)(Cc1ccc(O)cc1)C(=O)O,1467,-1.0,metirosine,tyrosine hydroxylase inhibitor,TH
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,1468,-1.0,palovarotene,retinoid receptor agonist,RARG
COc1cc(Br)c(Nc2nc(-c3c(C)nc4ncccn34)cs2)c(Br)c1,1469,0.83751995,PTC-209,BMI-1 inhibitor,
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,1470,0.5462853729999999,alvespimycin,HSP inhibitor,HSP90AA1
Clc1cnccn1,1471,-1.0,2-Chloropyrazine,,
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)(C)O)C[C@@H](O)C[C@@H]1O,1472,0.770811061,ercalcitriol,vitamin D receptor agonist,VDR
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2,1473,1.0459361679999999,trequinsin,phosphodiesterase inhibitor,PDE5A
Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc21,1474,-1.0,ramosetron,serotonin receptor antagonist,HTR3A
NCC(=O)N[C@@H](CCC(N)=O)C(=O)O,1475,-1.0,gly-gln,,
O=C(O)P(=O)(O)O,1476,0.938422415,foscarnet,DNA polymerase inhibitor,
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,1477,-1.0,fostamatinib,SYK inhibitor,SYK
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,1478,0.929808803,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7"
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,1479,0.7543359035,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR"
O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O,1480,-1.0,nifursol,bacterial DNA inhibitor,
CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,1481,1.3548739680000002,AZD2858,glycogen synthase kinase inhibitor,GSK3B
c1cncc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)c1,1482,0.872294146,WAY-600,mTOR inhibitor,MTOR
CCCCOc1ccc(C(=O)Nc2ccc(F)cc2F)cc1,1483,-1.0,VU0357121,glutamate receptor positive allosteric modulator,GRM5
COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@@H](C)C2,1484,-1.0,schisandrin-b,antioxidant,ATR
Nc1c[n+](N2CCOCC2)no1,1485,-1.0,linsidomine,nitric oxide donor,
NC(=S)NN=Cc1ccncc1,1486,-1.0,perchlozone,,
CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,1487,-1.0,landiolol,adrenergic receptor antagonist,ADRB1
O=C(NO)c1cnc(N2CCN(S(=O)(=O)c3ccc4ccccc4c3)CC2)nc1,1488,0.79966905,R306465,HDAC inhibitor,
CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC,1489,0.6604270489999999,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9"
O=Cc1ccc(CO)o1,1490,-1.0,5-HMF,,
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,1491,-1.0,asunaprevir,HCV inhibitor,
NC(=O)/N=N/C(N)=O,1492,1.252523412,azodicarbonamide,DNA synthesis inhibitor,
CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc12,1493,-1.0,beta-CCB,benzodiazepine receptor ligand,"GABRA1, GABRG2"
COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1,1494,-1.0,sulfameter,dihydrofolate reductase inhibitor,DHFR
CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](/C=C(\C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1,1495,0.501165017,taltobulin,tubulin polymerization inhibitor,
Nc1nc2c(sc(=O)n2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,1496,-1.0,"5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",,
CCCCCCCCCCCCCCCC[n+]1ccccc1,1497,0.7543667409999999,cetylpyridinium,,
CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,1498,0.912747023,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3"
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O,1499,-1.0,mizoribine,"immunosuppressant, inosine monophosphate dehydrogenase inhibitor",IMPDH1
CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,1500,-1.0,GW-4064,FXR agonist,NR1H4
CCOc1ccccc1C(N)=O,1501,-1.0,ethenzamide,analgesic agent,
COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,1502,-1.0,thonzylamine,antihistamine,
O=C(CNC(=O)c1ccc(Cl)cc1)NO,1503,-1.0,benurestat,urease inhibitor,
COC(=O)C1=CCCN(C)C1,1504,-1.0,arecoline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4"
Cl/C=C\C[N+]12CN3CN(CN(C3)C1)C2,1505,-1.0,"1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium",,
O=c1c(-c2ccc(O)cc2)coc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(O)ccc12,1506,-1.0,puerarin,serotonin receptor antagonist,
C/C(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc12)c1ccccn1,1507,0.7175034579999999,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14
Cc1cc(O)ccc1Cl,1508,-1.0,chlorocresol,ryanodine receptor activator,
CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O,1509,-1.0,CTS21166,beta-secretase inhibitor,BACE1
N#C/C(=C\c1ccc(O)c(O)c1)C(=O)OCCc1cccs1,1510,-1.0,2-TEDC,lipoxygenase inhibitor,ALOX12
CCn1c(O)nc2cc(Cl)c(Cl)cc21,1511,0.8688184590000001,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4"
C=CCN=C(N)S,1512,-1.0,allylthiourea,nitrification inhibitor,
OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O,1513,-1.0,1-deoxymannojirimycin,alpha mannosidase inhibitor,MAN2A1
O=C(O)CCC(=O)C(=O)O,1514,-1.0,2-oxoglutaric-acid,,OXGR1
COc1ccc(-n2nc(CCC(=O)N(C)O)cc2-c2ccc(Cl)cc2)cc1,1515,1.0163336945,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5
CCCc1ncc(C[n+]2ccccc2C)c(N)n1,1516,1.139709646,amprolium,thiamine uptake blocker,
Ic1cncc(OC[C@@H]2CCN2)c1,1517,-1.0,5-iodo-A-85380,acetylcholine receptor agonist,
COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC,1518,-1.0,thiophanate,,
Cc1ccc2c(Cl)cc(Cl)c(O)c2n1,1519,0.9485875429999999,chlorquinaldol,other antibiotic,
NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,1520,0.771333376,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,1521,-1.0,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1
COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,1522,-1.0,bedaquiline,ATPase inhibitor,
CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,1523,-1.0,KRN-633,VEGFR inhibitor,"FLT1, FLT4, KDR"
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1524,-1.0,vancomycin,bacterial cell wall synthesis inhibitor,
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)C=C4)C=C3)c1,1525,-1.0,m-THP,,
Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1,1526,-1.0,piceatannol,SYK inhibitor,"ATP5A1, ATP5B, ATP5C1, IRF3"
O=C(O)/C=C/CO,1527,1.261219038,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,
c1ccc2sc(N3CCN(Cc4ccc5c(c4)OCO5)CC3)nc2c1,1528,-1.0,2-[1-(4-piperonyl)piperazinyl]benzothiazole,serotonin receptor agonist,HTR4
C(=C/c1ccccc1)\CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,1529,-1.0,GBR-12783,dopamine uptake inhibitor,
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1530,-1.0,pimecrolimus,calcineurin inhibitor,"FKBP1A, MTOR"
O=C(O)Cc1ccc2c(c1)C(=O)c1ccccc1CO2,1531,-1.0,isoxepac,anti-inflammatory agent,
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3,1532,0.062235895,exatecan-mesylate,topoisomerase inhibitor,TOP1
CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,1533,-1.0,"16,16-dimethylprostaglandin-e2",prostanoid receptor agonist,HPGD
NCCc1c[nH]c2ccc(C(N)=O)cc12,1534,-1.0,5-carboxamidotryptamine,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7"
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1535,0.787269278,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2"
Cc1onc(O)c1C[C@H](N)C(=O)O,1536,-1.0,AMPA-(S),glutamate receptor agonist,GRIN1
Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1,1537,-1.0,GBR-13069,dopamine uptake inhibitor,SLC6A3
CN1CCN(C2=Cc3ccccc3Oc3ccc(Cl)cc32)CC1,1538,-1.0,2-CMDO,dopamine receptor antagonist,"DRD2, DRD4"
CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1539,-1.0,rifaximin,RNA synthesis inhibitor,NR1I2
CC(=O)OCC(COC(C)=O)OC(C)=O,1540,-1.0,triacetin,,
N=C(N)c1ccc(/N=N/Nc2ccc(C(=N)N)cc2)cc1,1541,-1.0,diminazene-aceturate,angiotensin converting enzyme activator,"AOC1, PRDX5, PRSS1"
Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1,1542,1.355499449,cefpiramide,bacterial cell wall synthesis inhibitor,
Nc1nc2c(ncn2[C@@H]2O[C@@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,1543,-1.0,guanosine,,PNP
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,1544,-1.0,perflubron,contrast agent,
C=CCc1cccc(/C=N/NC(=O)CN2CCN(Cc3ccccc3)CC2)c1O,1545,1.3737828980000002,PAC-1,caspase activator,CASP3
COc1ccc(O)c(C(C)(C)C)c1,1546,-1.0,butylated-hydroxyanisole,antioxidant,
CC[C@@H](CO)NCCN[C@@H](CC)CO,1547,-1.0,ethambutol,bacterial cell wall synthesis inhibitor,
Cc1c(C(N)=O)cc([N+](=O)[O-])cc1[N+](=O)[O-],1548,-1.0,dinitolmide,,
CCC(C)(C)O,1549,-1.0,amylene-hydrate,local anesthetic,
CC(=O)Nc1ccc(OC(C)=O)cc1,1550,-1.0,diacetamate,,
CN(C)CCc1ccc(O)cc1,1551,-1.0,hordenine,,
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1552,1.237187937,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ"
C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C,1553,1.191292478,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG"
COc1ccc(C(C)=O)c(O)c1,1554,-1.0,paeonol,anti-inflammatory agent,
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1555,-1.0,daptomycin,bacterial cell wall synthesis inhibitor,
CC(=O)O/N=C1/C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc21,1556,0.921605703,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,
CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1,1557,1.164712542,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1
O=C(O)c1cc(=O)c2ccccc2o1,1558,0.9418186820000001,chromocarb,antispasmodic,
CC1(C)CC(O)CC(C)(C)N1O,1559,-1.0,tempol,free radical scavenger,
COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1560,-1.0,beta-funaltrexamine,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1"
CCCC[C@@H](CC)COC(=O)c1ccccc1O,1561,-1.0,octisalate,,
C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1,1562,-1.0,dienestrol,estrogen receptor agonist,ESR1
C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C/C(=N/OCCN)CC[C@@]43C)[C@@H]1CCC2=O,1563,-1.0,istaroxime,ATPase inhibitor,ATP1A1
Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,1564,0.8414360879999999,PHA-665752,c-Met inhibitor,MET
CCCCCCCC/C=C\CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,1565,1.284469507,OLDA,TRPV agonist,GPR119
O=C(/C=C/c1ccc2ccccc2n1)c1ccncc1,1566,0.948458703,PFK-015,phosphofructokinase inhibitor,PFKFB3
Cc1c(NC(=O)N2CCOCC2)ccc2c1c1ccccc1n2C(C)C,1567,-1.0,NPY-5RA972,neuropeptide receptor antagonist,NPY5R
COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,1568,-1.0,MK-3697,orexin receptor antagonist,HCRTR2
O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,1569,0.9721640340000001,SRT1720,SIRT activator,SIRT1
CC(C)Nc1ncccn1,1570,-1.0,isaxonine,nerve growth factor agonist,
CC(=O)N1CCN(C)CC1,1571,-1.0,1-acetyl-4-methylpiperazine,acetylcholine receptor agonist,
CC[C@@H]1[C@@H](C)O[C@@](O)([C@@H](C)[C@H](O)[C@H](C)[C@H]2OC(=O)/C=C/C=C/[C@H](C)[C@H]([C@@H](C)[C@@H](O)[C@H](C)[C@@]3(O)C[C@@H](O[C@H]4C[C@H](O)[C@H](O)[C@H](C)O4)[C@H](CC)[C@@H](C)O3)OC(=O)/C=C/C=C/[C@H]2C)C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1,1572,0.790581621,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,
CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C,1573,-1.0,enoxolone,gap junction modulator,HSD11B1
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,1574,1.239603928,cidofovir,DNA polymerase inhibitor,
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,1575,0.77679156,adefovir-dipivoxil,DNA polymerase inhibitor,
O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1,1576,1.33525669,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA
COc1cc(/C=C/c2ccc(OC)cc2OC)cc(OC)c1,1577,1.004577215,TMS,,
Cc1c(C(=O)Nc2ccc(N3CCC(N4CCOCC4)CC3)c(C#N)c2)cnn1-c1ccc(Cl)cc1,1578,1.217047408,Y-320,interleukin inhibitor,IL17A
COc1cc(O)cc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)cc3O2)c1,1579,-1.0,neohesperidin,,
COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@@H]13)OCO4,1580,0.8460251409999999,harringtonine,protein synthesis inhibitor,
C1=C2CCCN[C@H]2[C@@H]2C[C@H]1[C@H]1CCCCN1C2,1581,-1.0,aloperine,,
CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1,1582,-1.0,chloramphenicol-palmitate,protein synthesis inhibitor,
O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(c2ccccc2)CC1,1583,-1.0,pelanserin,serotonin receptor antagonist,HTR2A
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](O)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1584,0.8622687640000001,10-deacetylbaccatin,antitumor agent,
CC(C)COC(=O)c1ccc(N)cc1,1585,-1.0,isobutamben,local anesthetic,
Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,1586,-1.0,calcium-levofolinate,,
N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1,1587,-1.0,capadenoson,adenosine receptor agonist,ADORA1
C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](OC(=O)OCC)c1ccnc2ccc(OC)cc12,1588,-1.0,quinine-ethyl-carbonate,,
CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21,1589,-1.0,TG-003,CLK inhibitor,"CLK1, CLK4, DYRK1A, DYRK1B"
N[C@@H](CC(=O)O)C(=O)O,1590,-1.0,L-Aspartic-Acid,metallic radical formation stimulant,"ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13"
COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,1591,-1.0,benidipine,calcium channel blocker,"CACNA1C, CACNA1G"
C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,1592,-1.0,gestodene,contraceptive agent,
CN1CCN(CC/C=C2\c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,1593,-1.0,thiothixene,dopamine receptor antagonist,"DRD1, DRD2, HRH1, HTR2A"
COc1ccc(Cc2cnc(N)nc2N)cc1OC,1594,1.183801472,diaveridine,dihydrofolate reductase inhibitor,
COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,1595,1.0,BMS-626529,HIV attachment inhibitor,
COc1ccc(CNC(=O)/C=C/c2ccc3[nH]cc(CCN(C)C)c3c2)cc1,1596,-1.0,GR46611,serotonin receptor agonist,HTR1D
Cc1cc(C)cc(C(=O)N(C)[C@H](Cc2ccc(-c3ccccc3)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)O)c1,1597,-1.0,IRL-2500,endothelin receptor antagonist,EDNRB
N#Cc1c(N2C[C@@H]3NCCO[C@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1598,1.4774921559999998,finafloxacin,bacterial DNA gyrase inhibitor,
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O,1599,-1.0,salirasib,mTOR inhibitor,TRPA1
C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21,1600,0.862643266,parthenolide,NFkB pathway inhibitor,
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,1601,-1.0,ezatiostat,glutathione transferase inhibitor,GSTP1
CC(=O)Nc1cc([As](=O)(O)O)ccc1O,1602,-1.0,acetarsol,,
O=C(NNc1ccccc1)c1ccncc1,1603,-1.0,plurisin-#1,stearoyl-CoA desaturase inhibitor,SCD
C/C(=N\NC(=S)N1CCC1)c1ccccn1,1604,0.44342189299999996,NSC-319726,p53 activator,
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I,1605,-1.0,metrizoic-acid,radiopaque medium,
O=P(O)(O)F,1606,-1.0,sodium-monofluorophosphate,,PYGM
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,1607,0.559857927,plinabulin,tubulin polymerization inhibitor,
Cc1nn(-c2ccccc2)c(C)c1/C=N/N1CCN(Cc2ccccc2)CC1,1608,-1.0,SANT-1,smoothened receptor antagonist,"SHH, SMO"
CCS(=O)(=O)N(C)[C@@H]1c2cc(C#N)ccc2OC(C)(C)[C@H]1O,1609,-1.0,chromanol-(+/-),potassium channel blocker,
O=C(O)C(=O)O,1610,-1.0,bismuth-oxalate,,
CC(C)O,1611,-1.0,indium(iii)-isopropoxide,,
NC(=S)N/N=C/c1coc2ccccc2c1=O,1612,-1.0,FPA-124,AKT inhibitor,
CC(O)C(=O)O,1613,1.28853109,ammonium-lactate,,HCAR1
N[C@@]1(C(=O)O)CC[C@H](C(=O)O)C1,1614,-1.0,cis-ACPD,glutamate receptor agonist,"GRM2, GRM3, GRM6, GRM7, GRM8"
Brc1cc2c(cc1[C@@H]1Nc3ccccc3[C@@H]3C=CC[C@@H]31)OCO2,1615,-1.0,G-15,estrogen receptor antagonist,GPER1
O=C(O)CC(O)(CC(=O)O)C(=O)O,1616,-1.0,lithium-citrate,,
O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1617,-1.0,sodium-gluconate,,
O=S(=O)(O)C(F)(F)F,1618,-1.0,bismuth(iii)-trifluoromethanesulfonate,direct substitution catalyst,
N[C@@H](C(=O)O)[C@@H](OCc1ccccc1)C(=O)O,1619,-1.0,TBOA-(DL),excitatory amino acid transporter inhibitor,"SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7"
O=[Si]=O,1620,-1.0,talc,,
CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1,1621,0.941036733,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G"
CC(C)(C)CC(C)(C)c1ccc(O)cc1,1622,-1.0,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2"
C=CCN,1623,1.097298552,sevelamer,phosphate antagonist,
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCC[N+](C)(C)C,1624,-1.0,phosphatidylcholine,,PCTP
